<SEC-DOCUMENT>0001193125-26-183535.txt : 20260428
<SEC-HEADER>0001193125-26-183535.hdr.sgml : 20260428
<ACCEPTANCE-DATETIME>20260428072406
ACCESSION NUMBER:		0001193125-26-183535
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20260428
DATE AS OF CHANGE:		20260428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sensei Biotherapeutics, Inc.
		CENTRAL INDEX KEY:			0001829802
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-295362
		FILM NUMBER:		26903134

	BUSINESS ADDRESS:	
		STREET 1:		1405 RESEARCH BLVD, SUITE 125
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(240) 243-8000

	MAIL ADDRESS:	
		STREET 1:		1405 RESEARCH BLVD, SUITE 125
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>d133316ds3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML><HEAD>
<TITLE>S-3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on April&nbsp;28, 2026 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-&#8194;&#8194;&#8194;&#8194;&#8194; </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-3</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Sensei Biotherapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">83-1863385</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1405 Research Boulevard </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Suite 125 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Rockville, MD
20850 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(240) <FONT STYLE="white-space:nowrap">243-8000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Christopher W. Gerry </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>President and General Counsel </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Sensei Biotherapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1405 Research Boulevard </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Suite 125 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Rockville, MD
20850 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ariel
Rom </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Mark Ballantyne </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Divakar Gupta </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Madison A.
Jones </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Rama Padmanabhan </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1299
Pennsylvania Avenue, NW, Suite 700 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20004 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(202) <FONT STYLE="white-space:nowrap">842-7800</FONT> </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public</B>: From time to time after the effective date of this Registration
Statement. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans,
please check the following box:&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or
continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:&#8194;&#9746; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering:&#8194;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earliest effective registration statement for the same offering:&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this
Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following
box:&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I. D. filed
to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box:&#8194;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company,&#8221; and &#8220;emerging growth company&#8221; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. (Check one): </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until this registration
statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV STYLE="position:relative; overflow:visible; width:651pt; height:30pt; transform-origin:bottom left; transform: rotate(-90deg) translate(-100%, 100%) translateX(30pt);">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><FONT COLOR="#ff4338"><B>The information in this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell these
securities until the registration statement filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) is effective. This prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities,
in any jurisdiction where the offer or sale is not permitted </B></FONT></P></DIV><DIV STYLE="position:relative; overflow:visible; margin-left:48pt; margin-right:48pt; transform: translateY(-30pt);">
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED APRIL&nbsp;28, 2026
</B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g133316g03g03.jpg" ALT="LOGO" STYLE="width:3.39687in;height:1.19687in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Sensei Biotherapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>24,868,028 Shares </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Common
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Offered by the Selling Stockholders </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">This prospectus relates to the proposed resale or other disposition by the selling stockholders identified herein (the &#8220;Selling
Stockholders&#8221;), of up to (i) 10,425,531 shares (&#8220;Merger Conversion Shares&#8221;) of our common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), issuable upon the conversion of 10,425.531 shares (&#8220;Merger Preferred
Shares&#8221;) of our Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock, par value $0.0001 per share (&#8220;Series B Preferred Stock&#8221;), (ii) 14,440,395 shares of Common Stock (the &#8220;Private Placement
Conversion Shares&#8221;) issuable upon the conversion of 14,440.395 shares of our Series B Preferred Stock (the &#8220;Private Placement Preferred Shares&#8221;) and (iii) 2,102 shares of Common Stock (the &#8220;Warrant Conversion Shares&#8221;)
issuable upon exercise of a warrant (the &#8220;Warrant&#8221;) to purchase 2.1020 shares of Series B Preferred Stock (the &#8220;Warrant Preferred Shares&#8221;), which will be exercisable for shares of Common Stock upon conversion of the Series B
Preferred Stock. Subject to receiving approval by our stockholders of the issuance of shares of Common Stock upon conversion of Series B Preferred Stock and the change of control of our company in accordance with the Nasdaq Stock Market LLC
(&#8220;Nasdaq&#8221;) listing rules (the &#8220;Conversion Proposal&#8221;) and of a certificate of amendment to our amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock from 12,500,000 to
300,000,000 (the &#8220;Authorized Share Proposal&#8221; and, together with the Conversion Proposal, the &#8220;Required Company Stockholder Matters&#8221;) and certain beneficial ownership limitations set by each preferred stockholder, each share
of Series B Preferred Stock will automatically convert into 1,000 shares of Common Stock. The shares of Common Stock registered by this prospectus are referred to herein as the &#8220;Resale Shares.&#8221; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">The Merger Preferred Shares were issued to former stockholders of Faeth Holdings Therapeutics, Inc., a Delaware corporation (&#8220;Faeth
HoldCo&#8221;), and the Warrant held by a former equityholder of Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of Faeth HoldCo (&#8220;Faeth Subsidiary&#8221; and, together with Faeth HoldCo,
&#8220;Faeth&#8221; or &#8220;Faeth Therapeutics&#8221;) was assumed by us and converted into a warrant to purchase our Series B Preferred Stock, in connection with our acquisition (the &#8220;Acquisition&#8221;) of Faeth Therapeutics, which closed
on February&nbsp;17, 2026. The Private Placement Preferred Shares were issued and sold to accredited investors in a private placement (the &#8220;2026 Private Placement&#8221; and, together with the Acquisition and the other transactions and actions
contemplated by the Merger Agreement, the &#8220;Acquisition Transactions&#8221;), which closed on February&nbsp;20, 2026. We are not offering or selling any Resale Shares under this prospectus and will not receive any of the proceeds from the sale
or other disposition of Resale Shares by the Selling Stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">The Selling Stockholders may sell the Resale Shares on any national
securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, on the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, in one or more transactions
otherwise than on these exchanges or systems, such as privately negotiated transactions, or using a combination of these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of
sale, or at negotiated prices. See the disclosure under the heading &#8220;Plan of Distribution&#8221; elsewhere in this prospectus for more information about how the Selling Stockholders may sell or otherwise dispose of their Resale Shares
hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">The Selling Stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in
what amount the Selling Stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">You should carefully read this prospectus and any applicable prospectus supplement, as well as any documents incorporated by reference herein or
therein, before you invest in any of the securities being offered. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Our Common Stock is traded on the Nasdaq Capital Market under the symbol
&#8220;SNSE.&#8221; On April&nbsp;24, 2026, the last reported sales price for our Common Stock was $31.79 per share. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>An investment in our securities involves a high degree of risk. You should carefully consider the information under the heading &#8220;<A HREF="#toc133316_4">Risk
 Factors</A>&#8221; beginning on page 8 of this prospectus and any applicable prospectus supplement, and under similar headings in the other documents that are incorporated by reference into this prospectus. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is
truthful or complete. Any representation to the contrary is a criminal offense. The securities are not being offered in any jurisdiction where the offer is not permitted. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is &#8195;&#8195;&#8195;&#8195;, 2026 </B></P></DIV> <p STYLE="clear:both; font-size:1pt; height:0">&nbsp;</p>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc133316_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc133316_2">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc133316_3">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc133316_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc133316_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc133316_6">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc133316_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc133316_8">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc133316_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc133316_10">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc133316_11">INCORPORATION OF INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc133316_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the SEC using a
&#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, offer and sell the securities described in this prospectus in one or more offerings. Information about the Selling
Stockholders may change over time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities the Selling Stockholders may
offer. Each time the Selling Stockholders sell shares of Common Stock using this prospectus, to the extent necessary and required by law, we will provide a prospectus supplement that will contain specific information about the terms of that
offering, including the number of shares of Common Stock being offered, the manner of distribution, the identity of any underwriters or other counterparties and other specific terms related to the offering. The prospectus supplement may also add,
update or change information contained in this prospectus. To the extent that any statement made in a prospectus supplement is inconsistent with statements made in this prospectus, the statements made in this prospectus will be deemed modified or
superseded by those made in the prospectus supplement. You should read this prospectus, any applicable prospectus supplement and the information incorporated by reference in this prospectus before making an investment in shares of our Common Stock.
See &#8220;Where You Can Find More Information&#8221; for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains and incorporates by reference
information that you should consider when making your investment decision. Neither we nor the Selling Stockholders have authorized anyone to give any information or to make any representation other than those contained or incorporated by reference
in this prospectus. The Selling Stockholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. We have not authorized anyone to provide you with different information. This prospectus
and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in any accompanying prospectus supplement or an offer to sell or the solicitation
of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference herein
and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus, unless the context otherwise requires, the terms (i) &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221;
&#8220;Sensei,&#8221; the &#8220;Company&#8221; and other similar terms refer to the business and operations of Sensei Biotherapeutics, Inc. and its consolidated subsidiaries for periods prior to the Acquisition and to Sensei Biotherapeutics, Inc.
and its consolidated subsidiaries, including Faeth Therapeutics for periods after the Acquisition; (ii) &#8220;Faeth HoldCo&#8221; refers to Faeth Holdings Therapeutics, Inc., (iii) &#8220;Faeth Subsidiary&#8221; refers to Faeth Therapeutics, LLC, a
wholly owned subsidiary of Faeth HoldCo, (iv) &#8220;Faeth&#8221; or &#8220;Faeth Therapeutics&#8221; refer collectively to Faeth HoldCo and Faeth Subsidiary and (v) &#8220;Acquisition&#8221; refers to the acquisition by the Company of Faeth
Therapeutics pursuant to that Agreement and Plan of Merger, dated February&nbsp;17, 2026, by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company, Sapphire Second Merger Sub,
LLC, a Delaware limited liability company and wholly owned subsidiary of the Company, Faeth HoldCo and Faeth Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the&nbsp;<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.
We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States, neither we nor the Selling Stockholders have done anything that would permit the offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to the offering and
the distribution of this prospectus outside of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc133316_2"></A>CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, including the documents that we incorporate by reference, contains &#8220;forward-looking statements&#8221; within
the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These forward-looking statements
involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. These
statements are based on current expectations of future events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All statements, other than statements of historical facts contained in
this prospectus, are forward-looking statements, including, without limitation, statements regarding: the Required Company Stockholder Matters, the Annual Meeting (as defined below), the Nasdaq Listing Application (as defined below), the expected
Company name and ticker if the Required Company Stockholder Matters and the Nasdaq Listing Application are approved, our ability to achieve the expected benefits or opportunities with respect to the Acquisition, our future results of operations and
financial position, business strategy, our expectations that our cash and cash equivalents, together with the proceeds from the 2026 Private Placement, will enable us to fund our operating expenses and capital expenditure requirements through
topline data readouts from both our ongoing Phase 2 trial of PIKTOR in advanced endometrial cancer (Study <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FTH-PIK-201)</FONT></FONT> and our planned Phase 1b trial of PIKTOR in
HR+/HER2- advanced breast cancer (Study <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FTH-PIK-101),</FONT></FONT> our preclinical and clinical development activities, the potential therapeutic benefits and economic value of our
product candidates, and the timing and results of preclinical studies and clinical trials. Forward-looking statements generally relate to future events or our future financial or operating performance. The words &#8220;aim,&#8221;
&#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;designed to,&#8221; &#8220;estimate,&#8221; &#8220;evaluate,&#8221; &#8220;expect,&#8221; &#8220;explore,&#8221;
&#8220;intend,&#8221; &#8220;intended to,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221;
&#8220;pursue,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;to be,&#8221; &#8220;will,&#8221; and &#8220;would,&#8221; or the negative of such terms or other similar expressions that convey uncertainty of future events or outcomes are
intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These
forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to
predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may
make. Factors that might cause such a difference include those discussed in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as supplemented and updated by subsequent Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> that we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus, as well as
the risk factors and other information contained in or incorporated by reference into any accompanying prospectus supplement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this
prospectus or, in the case of documents referred to or incorporated by reference, the date of those documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements
that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this prospectus. While we believe that such information
provides a reasonable basis for these statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These
statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All subsequent written or oral
forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly
any revisions to these forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S. securities laws. If we do
update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc133316_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary may not contain all the information that you should consider before investing in securities. You should read the entire
prospectus and the information incorporated by reference in this prospectus carefully, including &#8220;Risk Factors&#8221; and the financial data and related notes and other information incorporated by reference herein, before making an investment
decision. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. On February&nbsp;17, 2026, we completed the acquisition of Faeth Therapeutics, a
clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The Acquisition brought Faeth&#8217;s lead asset, PIKTOR, a proprietary investigational <FONT STYLE="white-space:nowrap">all-oral</FONT>
combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway, into our pipeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the
Acquisition, our lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The PI3K/AKT/mTOR pathway is dysregulated in up to 50% of all solid tumors, making it one
of the most prevalent therapeutic targets in oncology. Despite this, currently approved therapies &#8212; all of which target only a single pathway node &#8212; have produced limited clinical benefits, often accompanied by toxicities that have
constrained their utilization. Our core scientific thesis is that simultaneously suppressing multiple nodes of a pathway produces deeper, more durable tumor suppression than targeting any single-node alone, which we believe may also enable lower
drug dosing, potentially contributing to an improved tolerability profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PIKTOR is currently being evaluated in an ongoing Phase 2
trial in second-line advanced endometrial cancer (Study <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FTH-PIK-201),</FONT></FONT> with topline data anticipated by <FONT STYLE="white-space:nowrap">year-end</FONT> 2026, and we
intend to initiate a Phase 1b trial in HR+/HER2- advanced breast cancer (Study <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FTH-PIK-101)</FONT></FONT> by the first half of 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Faeth was <FONT STYLE="white-space:nowrap">co-founded</FONT> in 2019 by Anand Parikh and Oliver Maddocks, PhD, together with scientific
founders Lewis Cantley, PhD, the discoverer of the PI3K pathway, Siddhartha Mukherjee, MD, DPhil, Karen Vousden, PhD, Scott Lowe, PhD, and Greg Hannon, PhD. We are led by an experienced management team with expertise spanning cancer biology,
translational research, clinical drug development, regulatory affairs and corporate strategy gained through prior roles within both biotechnology and large pharmaceutical companies as well as academia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g133316g08g08.jpg" ALT="LOGO" STYLE="width:6.32in;height:2.39333in;">
 </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to PIKTOR and the Faeth pipeline programs described above, our pipeline includes
programs that preceded the Acquisition. We are completing a Phase 1/2 trial of solnerstotug (formerly <FONT STYLE="white-space:nowrap">SNS-101),</FONT> our conditionally active monoclonal antibody targeting the immune checkpoint VISTA. As of
March&nbsp;23, 2026, seven patients remain on study in the expansion portion of the trial. We also have three preclinical-stage conditionally active antibody programs: <FONT STYLE="white-space:nowrap">SNS-102</FONT> (targeting VSIG4), <FONT
STYLE="white-space:nowrap">SNS-103</FONT> (targeting CD39), and <FONT STYLE="white-space:nowrap">SNS-201,</FONT> a bispecific antibody designed to conditionally activate CD28 through monovalent CD28 engagement and bivalent <FONT
STYLE="white-space:nowrap">pH-selective</FONT> VISTA binding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;17, 2026 (the &#8220;Closing&#8221;), we completed the acquisition of Faeth Therapeutics in accordance with the terms of the
Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), dated February&nbsp;17, 2026, by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;First Merger
Sub&#8221;), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (&#8220;Second Merger Sub&#8221;), Faeth HoldCo and Faeth Subsidiary, pursuant to which, First Merger Sub merged with and
into Faeth HoldCo, pursuant to which Faeth HoldCo was the surviving corporation and became a wholly owned subsidiary of the Company (the &#8220;First Merger&#8221;). Immediately following the First Merger, Faeth HoldCo merged with and into Second
Merger Sub, pursuant to which Second Merger Sub was the surviving entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Acquisition was structured as a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">stock-for-stock</FONT></FONT> transaction pursuant to which all of Faeth Therapeutics&#8217; outstanding equity interests were exchanged based on a fixed exchange ratio for aggregate
consideration of 10,497.098 shares of Series B Preferred Stock, each share of which is convertible into 1,000 shares of Common Stock (representing 10,497,098 shares on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">as-converted-to-common</FONT></FONT></FONT> basis and without giving effect to any beneficial ownership limitations), subject to receipt of approval of the Required Company Stockholder Matters in accordance with Nasdaq
listing rules and the beneficial ownership limitations set by each holder, which may be waived by each holder at any time following the approval by Nasdaq of a Nasdaq initial listing application filed in accordance with Nasdaq listing rule 5110(a)
(the &#8220;Nasdaq Listing Application&#8221;) and approval of the Required Company Stockholder Matters. In addition, the outstanding warrant to purchase shares of Faeth Subsidiary capital stock was converted into a warrant to purchase an aggregate
of 2.1020 shares of Series B Preferred Stock (representing a warrant to purchase 2,102 shares of Common Stock on an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-common</FONT></FONT></FONT> basis and without giving effect to any beneficial ownership limitations) and all outstanding options to
purchase Faeth Subsidiary common stock were assumed by us and converted into options to purchase an aggregate of 252,210 shares of Common Stock. The Series B Preferred Stock was a newly designated series of preferred stock and was intended to have
economic rights equivalent to our Common Stock, but with no voting rights. The rights of the Series B Preferred Stock are set forth in the Certificate of Designation of Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible
Preferred Stock (the &#8220;Certificate of Designation&#8221;) that we filed with the Secretary of State of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With
respect to the Acquisition, we determined that we were the acquiror for accounting purposes under <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ASC&nbsp;805-10-25-4&nbsp;and</FONT></FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ASC&nbsp;805-10-55-11.&nbsp;The</FONT></FONT></FONT> primary factors considered were (a)&nbsp;the relative voting rights in the combined entity not
resulting in a change of control, <FONT STYLE="white-space:nowrap">(b)&nbsp;the&nbsp;pre-Acquisition&nbsp;members</FONT> of our board of directors maintained control of our board of directors, and
<FONT STYLE="white-space:nowrap">(c)&nbsp;the&nbsp;pre-Acquisition&nbsp;members</FONT> of senior management remained the same at the closing of the Acquisition Transactions, other than the newly appointed Chief Operating Officer. Next, we considered
whether the Acquisition should be defined as a business under ASC 805.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ASC&nbsp;805-10-55-5A&nbsp;through&nbsp;55-5C&nbsp;describe</FONT></FONT></FONT></FONT> a screen test to determine
whether an acquired set of assets and activities is not a business. We determined that substantially all (greater than 90%) of the fair value of the assets acquired were concentrated in a single asset, PIKTOR, an investigational, proprietary, <FONT
STYLE="white-space:nowrap">all-oral</FONT> combination of serabelisib and sapanisertib that is designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting. Accordingly, we treated the Acquisition as
an asset acquisition for accounting purposes. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the Acquisition, we entered into a Securities Purchase Agreement (the
&#8220;Purchase Agreement&#8221;) with the purchasers named therein (the &#8220;Investors&#8221;), pursuant to which, on February&nbsp;20, 2026 (the &#8220;PIPE Closing&#8221;), we issued and sold an aggregate of 14,440.395 shares of Series B
Preferred Stock, each share of which is convertible into 1,000 shares of Common Stock (representing 14,440,395 shares on an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-common</FONT></FONT></FONT> basis and without giving effect to any beneficial ownership limitations), subject to receipt of approval
of the Required Company Stockholder Matters in accordance with Nasdaq listing rules and the beneficial ownership limitations set by each holder, which may be waived by each holder at any time following the approval by Nasdaq of the Nasdaq Listing
Application and approval of the Required Company Stockholder Matters, at a price of $13,850 per share of Series B Preferred Stock (or approximately $13.85 per share on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">as-converted-to-common</FONT></FONT></FONT> basis) for aggregate gross proceeds of approximately $200&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;17, 2026, we entered into a Registration Rights Agreement (the &#8220;RRA&#8221;) with the Investors. Pursuant to the RRA, we
are obligated to prepare and file a resale registration statement with the SEC within 75 calendar days following the closing of the 2026 Private Placement. The RRA also contains customary terms, including an obligation to indemnify the Investors and
certain affiliates from certain liabilities relating to any misstatements or omissions in the resale registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Acquisition, the 2026 Private Placement and the other transactions and actions contemplated by the Merger Agreement (the &#8220;Acquisition Transactions&#8221;) were approved by our board of directors and the board of directors and stockholders of
Faeth Therapeutics. The closings of the Acquisition Transactions were not subject to the approval of Sensei stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a
definitive proxy statement with the SEC to solicit approval of the Required Company Stockholder Matters, among other matters, at our 2026 annual meeting of our stockholders (the &#8220;Annual Meeting&#8221;). Except as otherwise required by law
(e.g. voting on a change to the authorized shares of Series B Preferred Stock or the rights of such shares as required by the General Corporation Law of the State of Delaware (&#8220;DGCL&#8221;)) and the Certificate of Designation, the Series B
Preferred Stock does not have voting rights. For more information on the Series B Preferred Stock, please refer to the Certificate of Designation, which is incorporated by reference herein and attached as Exhibit 3.1 of our Current Report on Form <FONT
STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on February&nbsp;18, 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed the Nasdaq Listing Application with
Nasdaq. If the Required Company Stockholder Matters and the Nasdaq Listing Application are approved, it is expected that we will change our name to &#8220;Faeth Therapeutics, Inc.&#8221; and our Common Stock will trade on The Nasdaq Capital Market
under the symbol &#8220;FTH.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Merger Agreement, Sensei and Faeth Subsidiary entered into
stockholder support agreements (the &#8220;Support Agreements&#8221;) with certain of Sensei&#8217;s officers and directors (solely in their capacities as stockholders), representing 1.5% of the outstanding shares of Common Stock as of
April&nbsp;13, 2026. The Support Agreements provide that, among other things, each of the parties thereto has agreed to vote or cause to be voted all of the shares of Common Stock owned by such stockholder in favor of the Required Company
Stockholder Matters, the approval of the Company&#8217;s 2026 Equity Incentive Plan and the Company&#8217;s 2026 Employee Stock Purchase Plan at the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently and in connection with the execution of the Merger Agreement, certain officers, directors and certain stockholders of Faeth
HoldCo as of immediately prior to the Merger, and certain of the directors and officers of Sensei as of immediately prior to the Acquisition entered <FONT STYLE="white-space:nowrap">into&nbsp;lock-up&nbsp;agreements</FONT> (the <FONT
STYLE="white-space:nowrap">&#8220;Lock-up&nbsp;Agreements&#8221;)</FONT> with Sensei and Faeth Subsidiary, pursuant to which each such stockholder will be subject to <FONT STYLE="white-space:nowrap">a&nbsp;180-day&nbsp;lockup</FONT> on the sale or
transfer of shares of Common Stock and Series B Preferred Stock held by each such stockholder, subject to certain limited exceptions as set forth in the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information about the Acquisition Transactions, you should refer to our Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on February&nbsp;18, 2026, which is incorporated by reference herein. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were originally incorporated as Panacea Pharmaceuticals, Inc., or Panacea, under the laws of the state of Maryland in 1999. In December
2017, we reincorporated in Delaware and changed our name to Sensei Biotherapeutics, Inc. Our principal executive offices are located at 1405 Research Blvd, Rockville, MD 20850. Our telephone number is (240)
<FONT STYLE="white-space:nowrap">243-8000.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company,&#8221; as defined in Section&nbsp;2(a) of the Securities Act. For as long as we continue to be an
emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including the auditor attestation requirements in the assessment
of our internal control over financial reporting under Section&nbsp;404(b) of the Sarbanes-Oxley Act, compliance with any new requirements adopted by the PCAOB, disclosure obligations regarding executive compensation in our periodic reports and
proxy statements, and the requirements of holding advisory <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#8220;say-on-pay&#8221;</FONT></FONT> votes on executive compensation and stockholder advisory votes on golden parachute
compensation not previously approved. Certain of these reduced reporting requirements and exemptions are also available to us due to the fact that we qualify as a &#8220;smaller reporting company&#8221; under SEC rules. For instance, smaller
reporting companies are not required to obtain an auditor attestation and report regarding management&#8217;s assessment of internal control over financial reporting, are not required to provide a compensation discussion and analysis, are not
required to provide a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> graph or CEO pay ratio disclosure and may present only two years of audited financial statements and related MD&amp;A
disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, we will remain an emerging growth company until the earliest of (1)&nbsp;the last day of the fiscal year
in which we have more than $1.235&nbsp;billion in annual revenue; (2)&nbsp;the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700.0&nbsp;million of equity securities held by
<FONT STYLE="white-space:nowrap">non-affiliates;</FONT> (3)&nbsp;the issuance, in any three-year period, by our company of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; and
(4)&nbsp;December&nbsp;31, 2026, which is the last day of the fiscal year following the fifth anniversary of the date of the first sale of our Common Stock pursuant to an effective registration statement filed under the Securities Act. Under current
SEC rules, however, we will continue to qualify as a &#8220;smaller reporting company&#8221; for so long as (i)&nbsp;we have a public float (i.e., the market value of common equity held by <FONT STYLE="white-space:nowrap">non-affiliates)</FONT> of
less than $250&nbsp;million or (ii)&nbsp;our annual revenue is less than $100&nbsp;million during the most recently completed fiscal year and the market value of our Common Stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less
than $700&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies also can delay adopting new or revised accounting standards until
such time as those standards apply to private companies. We have elected not to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or
private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i)&nbsp;irrevocably elect to &#8220;opt out&#8221; of such extended
transition period or (ii)&nbsp;no longer qualify as an emerging growth company. Therefore, the reported results of operations contained in our consolidated financial statements may not be directly comparable to those of other public companies. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Common stock offered by the Selling Stockholders </P></TD>
<TD>Up to an aggregate of 24,868,028 shares of Common Stock, which consist of (i) 10,425,531 Merger Conversion Shares, (ii) 14,440,395 Private Placement Conversion Shares and (iii) 2,102 Warrant Conversion Shares. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Terms of the offering </P></TD>
<TD>Each selling stockholder will determine when and how it will sell the common stock offered in this prospectus, as described in &#8220;Plan of Distribution.&#8221; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We will not receive any proceeds from the sale of the Resale Shares. If the Warrant is exercised for cash, we will, however, receive the net proceeds thereof. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See &#8220;Risk Factors&#8221; on page 8 for a discussion of factors you should carefully consider before deciding to invest in our common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Capital Market symbol: </P></TD>
<TD>&#8220;SNSE&#8221; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc133316_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully
the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in our most recent Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> as supplemented and updated by subsequent Quarterly Reports on
Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> that we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus,
as well as the risk factors and other information contained in or incorporated by reference into any accompanying prospectus supplement. The risks described in these documents are not the only ones we face, but those that we consider to be material.
There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future results. Past financial performance may not be a reliable indicator of future
performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This
could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. Please also read carefully the section titled &#8220;Cautionary Statement Concerning Forward-Looking Statements.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc133316_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered
hereby. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. If the Warrant is exercised for cash, we will, however, receive the net proceeds thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to limited exceptions, the Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the
Selling Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of any of the Resale Shares. We will bear the costs, fees and expenses incurred in effecting the
registration of the Resale Shares covered by this prospectus, including all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accounting firm. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc133316_6"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus covers the resale or other disposition from time to time by the Selling Stockholders identified in the table below of up to an
aggregate of 24,868,028 shares of Common Stock, which consist of (i) 10,425,531 Merger Conversion Shares, (ii) 14,440,395 Private Placement Conversion Shares and (iii) 2,102 Warrant Conversion Shares. The Selling Stockholders may from time to time
offer and sell any or all of the Resale Shares set forth below pursuant to this prospectus and any accompanying prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
February&nbsp;17, 2026, we entered into the Purchase Agreement, pursuant to which we sold an aggregate of 14,440.395 shares of Series B Preferred Stock, which are convertible into 14,440,395 shares of Common Stock pursuant to the Certificate of
Designation, at an aggregate purchase price of approximately $200&nbsp;million. Also on February&nbsp;17, 2026, we completed our acquisition of Faeth Therapeutics in accordance with the Merger Agreement, pursuant to which we issued an aggregate of
10,497.098 shares of Series B Preferred Stock, which are convertible into 10,497,098 shares of Common Stock pursuant to the Certificate of Designation, and the outstanding warrant to purchase shares of Faeth Subsidiary capital stock was converted
into a warrant to purchase an aggregate of 2.1020 shares of Series B Preferred Stock, which will be exercisable for 2,102 shares of Common Stock upon conversion of the Series B Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the Resale Shares to permit the Selling Stockholders and their pledgees, donees, transferees or other <FONT
STYLE="white-space:nowrap">successors-in</FONT> interest that receive their shares after the date of this prospectus to resell or otherwise dispose of the shares in the manner contemplated under &#8220;Plan of Distribution&#8221; herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise disclosed herein, the Selling Stockholders do not have, and within the past three years have not had, any material
position, office or other material relationship with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the names of the Selling Stockholders, the number
of shares of our Common Stock owned by the Selling Stockholders, the number of shares of our Common Stock that may be offered under this prospectus and the number of shares of our Common Stock that will be owned after this offering by the Selling
Stockholders assuming all of the shares registered for resale hereby are sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may sell some, all or none of
their Resale Shares. We do not know how long the Selling Stockholders will hold the Resale Shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Stockholders regarding the sale or other
disposition of any of the Resale Shares, except for the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements. The Resale Shares covered hereby may be offered from time to time by the Selling Stockholders, provided that Resale Shares issued
upon conversion of Series B Preferred Stock may only be offered after such shares of Series B Preferred Stock are converted to Common Stock pursuant to the terms of the Certificate of Designation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information set forth below is based upon information obtained from the Selling
Stockholders and upon information in our possession regarding the issuance of the Series B Preferred Stock and the assumption of the Warrant in connection with the Acquisition Transactions. The percentages of Common Stock owned after the offering by
each Selling Stockholder below are based on 1,340,333 shares of Common Stock outstanding as of March&nbsp;31, 2026, and, for each Selling Stockholder, assumes the conversion of only the Series B Preferred Stock owned by such Selling Stockholder but
not the Series B Preferred Stock owned by any other Selling Stockholder and, assumes the exercise of the Warrant only for the Selling Stockholder who holds the Warrant. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Selling Stockholders<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock<BR>Beneficially<BR>Owned<BR>Before<BR>Offering<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock that<BR>May Be<BR>Offered<BR>Pursuant&nbsp;to<BR>Prospectus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock<BR>Beneficially<BR>Owned After<BR>Offering<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Suvretta Capital Management, LLC, investment manager for entities affiliated with Averill<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,020,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,985,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avoro Life Sciences Fund LLC<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,444,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,444,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Baker Bros. Advisors
LP<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,444,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,444,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atlas Private Holdings (Cayman)
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">902,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">902,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Global Healthcare GP, LLC, General Partner to Cormorant Global Healthcare Master Fund,
LP<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fairmount Healthcare Fund II L.P.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Logos Opportunities Fund V LP<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Healthcare Fund GP, LLC, General Partner of RA Capital Healthcare Fund, L.P.<SUP
STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Columbia Management Investment Advisers, LLC, Investment Manager to Seligman Healthcare Spectrum
(Master) Fund<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Vivo Opportunity
Fund<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with ADAR1 Capital
Management<SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">B Group Capital LLC<SUP STYLE="font-size:75%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">610,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">610,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts managed by Caligan
Partners<SUP STYLE="font-size:75%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">487,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ikarian Capital, LLC as investment advisor to entities affiliated with Boothbay<SUP
STYLE="font-size:75%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with EcoR1 Capital
LLC<SUP STYLE="font-size:75%; vertical-align:top">(19)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Franklin Advisers,
Inc.<SUP STYLE="font-size:75%; vertical-align:top">(20)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">494,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Octagon Investments Master Fund
LP<SUP STYLE="font-size:75%; vertical-align:top">(21)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SILV Fund, Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(22)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trails Edge Biotechnology Master Fund,
LP<SUP STYLE="font-size:75%; vertical-align:top">(23)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">486,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Woodline Master Fund LP<SUP STYLE="font-size:75%; vertical-align:top">(24)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ikarian Capital, LLC, Investment Manager to Ikarian Healthcare Master Fund, LP<SUP
STYLE="font-size:75%; vertical-align:top">(25)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">204,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boxer Capital Master Fund, LP<SUP STYLE="font-size:75%; vertical-align:top">(26)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Marshall Wace
LLP<SUP STYLE="font-size:75%; vertical-align:top">(27)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affinity Healthcare Fund, LP<SUP STYLE="font-size:75%; vertical-align:top">(28)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alyeska Master Fund, LP<SUP STYLE="font-size:75%; vertical-align:top">(29)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Special Situations
Fund<SUP STYLE="font-size:75%; vertical-align:top">(30)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Squadron Master Fund LP<SUP STYLE="font-size:75%; vertical-align:top">(31)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Able Partners NYC, LLC<SUP STYLE="font-size:75%; vertical-align:top">(32)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Selling Stockholders<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock<BR>Beneficially<BR>Owned<BR>Before<BR>Offering<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock that<BR>May Be<BR>Offered<BR>Pursuant&nbsp;to<BR>Prospectus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock<BR>Beneficially<BR>Owned After<BR>Offering<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with
AgFunder<SUP STYLE="font-size:75%; vertical-align:top">(33)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alpha Capital Corp.<SUP STYLE="font-size:75%; vertical-align:top">(34)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anand Parikh<SUP STYLE="font-size:75%; vertical-align:top">(35)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">804,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">761,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Angelle Advisors LLC<SUP STYLE="font-size:75%; vertical-align:top">(36)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anne C. Harrison<SUP STYLE="font-size:75%; vertical-align:top">(37)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Apple Island Investment Fund I<SUP STYLE="font-size:75%; vertical-align:top">(38)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bar Investments LLC<SUP STYLE="font-size:75%; vertical-align:top">(39)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benjamin D. Hopkins<SUP STYLE="font-size:75%; vertical-align:top">(40)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Burnett F. King<SUP STYLE="font-size:75%; vertical-align:top">(41)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantley GRAT Remainder Trust f/b/o Alexandra Cantley u/d/t 7/1/16<SUP
STYLE="font-size:75%; vertical-align:top">(42)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantley GRAT Remainder Trust f/b/o Mariko Cantley u/d/t 7/1/16<SUP
STYLE="font-size:75%; vertical-align:top">(42)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Cantos
Ventures<SUP STYLE="font-size:75%; vertical-align:top">(43)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Consolidated Investments International Series B<SUP
STYLE="font-size:75%; vertical-align:top">(44)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel J. Conway<SUP STYLE="font-size:75%; vertical-align:top">(45)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debbie Chirnomas<SUP STYLE="font-size:75%; vertical-align:top">(46)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domen Kampjut<SUP STYLE="font-size:75%; vertical-align:top">(47)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">FA-0611</FONT> Fund I, a series of Umami Capital, LP<SUP
STYLE="font-size:75%; vertical-align:top">(48)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Faeth Investments, LLC<SUP STYLE="font-size:75%; vertical-align:top">(49)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Felix Gurevich 2023 Family Trust<SUP STYLE="font-size:75%; vertical-align:top">(50)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fund I, a series of Avicella Capital Fund,
LP<SUP STYLE="font-size:75%; vertical-align:top">(51)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">249,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">249,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Future
Ventures<SUP STYLE="font-size:75%; vertical-align:top">(52)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,016,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,016,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Georgina F. Steele<SUP STYLE="font-size:75%; vertical-align:top">(53)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Hannon<SUP STYLE="font-size:75%; vertical-align:top">(54)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Mork<SUP STYLE="font-size:75%; vertical-align:top">(55)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with iSelect
Funds<SUP STYLE="font-size:75%; vertical-align:top">(56)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Javier Piggee<SUP STYLE="font-size:75%; vertical-align:top">(57)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jayson Dallas<SUP STYLE="font-size:75%; vertical-align:top">(58)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H. Jonathan G. Lindstr&ouml;m<SUP STYLE="font-size:75%; vertical-align:top">(59)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Karen H. Vousden<SUP STYLE="font-size:75%; vertical-align:top">(60)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Katelyn Patterson<SUP STYLE="font-size:75%; vertical-align:top">(61)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KdT Ventures Fund II, LP<SUP STYLE="font-size:75%; vertical-align:top">(62)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Khosla
Ventures<SUP STYLE="font-size:75%; vertical-align:top">(63)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,632,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,632,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lewis Cantley<SUP STYLE="font-size:75%; vertical-align:top">(64)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcus Goncalves<SUP STYLE="font-size:75%; vertical-align:top">(65)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Margao II, LP<SUP STYLE="font-size:75%; vertical-align:top">(66)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marina Sheyfer 2023 Family Trust<SUP STYLE="font-size:75%; vertical-align:top">(67)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mars Health Fund I, LLC<SUP STYLE="font-size:75%; vertical-align:top">(68)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oliver D.K. Maddocks<SUP STYLE="font-size:75%; vertical-align:top">(69)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">458,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">458,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Petros A. Tyrakis<SUP STYLE="font-size:75%; vertical-align:top">(70)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Gould<SUP STYLE="font-size:75%; vertical-align:top">(71)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ryan O&#8217;Connor<SUP STYLE="font-size:75%; vertical-align:top">(72)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ryan W. Whitney<SUP STYLE="font-size:75%; vertical-align:top">(73)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S2G Builders Food&nbsp;&amp; Agriculture Fund III,
LP<SUP STYLE="font-size:75%; vertical-align:top">(74)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,919,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,919,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Selling Stockholders<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock<BR>Beneficially<BR>Owned<BR>Before<BR>Offering<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock that<BR>May Be<BR>Offered<BR>Pursuant&nbsp;to<BR>Prospectus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock<BR>Beneficially<BR>Owned After<BR>Offering<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S3 Partners Group, LLLP<SUP STYLE="font-size:75%; vertical-align:top">(75)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8201;&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott W. Lowe<SUP STYLE="font-size:75%; vertical-align:top">(76)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Siddhartha Mukherjee<SUP STYLE="font-size:75%; vertical-align:top">(77)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Simon R.V. Knott<SUP STYLE="font-size:75%; vertical-align:top">(78)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen M. Hahn<SUP STYLE="font-size:75%; vertical-align:top">(79)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Todd A. Young<SUP STYLE="font-size:75%; vertical-align:top">(80)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Unshackled
Ventures<SUP STYLE="font-size:75%; vertical-align:top">(81)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Western Alliance Bancorp<SUP STYLE="font-size:75%; vertical-align:top">(82)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To our knowledge, unless otherwise indicated, all persons named in the table above have sole voting and
investment power with respect to their shares of Common Stock. Unless an address is provided below, the address for the holder is 75 State Street, Suite 100, Boston, MA 02109. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#8220;Beneficial ownership&#8221; is a term broadly defined by the SEC in Rule
<FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act, and includes more than the typical form of stock ownership, that is, stock held in the person&#8217;s name. The term also includes what is referred to as &#8220;indirect
ownership,&#8221; meaning ownership of shares as to which a person has or shares investment power. Notwithstanding the foregoing, the beneficial ownership amounts assume the sale of all Common Stock that may be offered pursuant to this prospectus
without taking into account certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred into shares of Common Stock (i)&nbsp;prior to the approval of the Required Company
Stockholder Matters and the Nasdaq Listing Application or (ii)&nbsp;if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder between 4.99% and
19.99%) (the &#8220;Beneficial Ownership Limitation&#8221;) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion, which Beneficial Ownership Limitation may be waived by each holder
at any time following the approval by Nasdaq of the Nasdaq Listing Application and approval of the Required Company Stockholder Matters. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; consist of
(i)&nbsp;1,693,082 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Averill Master Fund, Ltd. (&#8220;Averill Master&#8221;), (ii) 292,472 shares of Common Stock issuable upon conversion of shares of
Series B Preferred Stock held by Averill Madison Master Fund, Ltd. (&#8220;Averill Madison&#8221;), (iii) 29,570 shares of Common Stock held by Averill Master and (iv) 4,979 shares of Common Stock held by Averill Madison. The shares reported under
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of the 1,693,082 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Averill Master in the 2026 Private Placement and the
292,472 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Averill Madison in the 2026 Private Placement. The shares reported under &#8220;Common Stock Beneficially Owned After Offering&#8221; consist of
(i) 29,570 shares of Common Stock held by Averill Master (ii) 4,979 shares of Common Stock held by Averill Madison. Suvretta Capital Management, LLC (&#8220;Suvretta&#8221;) is the investment manager of Averill Master and Averill Madison. Aaron
Cowen is a control person of Suvretta and as such may be deemed to beneficially own these shares. Mr.&nbsp;Cowen disclaims beneficial ownership of all shares of Common Stock beneficially held by Averill Master and Averill Madison, other than, to the
extent of any pecuniary interest therein. The address of the principal business office of Suvretta, Mr.&nbsp;Cowen, Averill Master and Averill Madison is 540 Madison Avenue, 7th Floor, New York, NY 10022. The shares of Common Stock issuable upon
conversion of the shares of Series B Preferred Stock held by Averill Master and Averill Madison are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 1,444,039 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Avoro Life Sciences Fund LLC (&#8220;Avoro&#8221;), all of
which were issued in the 2026 Private Placement. Avoro Capital Advisors LLC (&#8220;Avoro Capital&#8221;) is the investment advisor for Avoro. Behzad Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital and may be deemed
to have investment discretion and voting power over the shares held by Avoro. Dr.&nbsp;Aghazadeh disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. The address of Avoro is 110
Greene Street, Suite 800, New York, NY 10012. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Avoro are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of (i) 1,364,936 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Baker Brothers Life Sciences, L.P. (&#8220;BBLS&#8221;)
and (ii) 79,103 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by 667, L.P. (&#8220;667, L.P.&#8221; and together with BBLS, the &#8220;Baker Funds&#8221;), all of which were issued in the 2026 Private
Placement. Baker Bros Advisors LP is the management company and investment advisor to the Baker Funds and has sole voting and investment power with respect to the shares held by the Baker Funds. Baker Bros. Advisors (GP) LLC is the sole general
partner of Baker Bros. Advisors LP. Julian C. Baker and Felix J. Baker are managing members of Baker Bros. Advisors (GP) LLC. Baker Bros. Advisors (GP) LLC, Felix J. Baker, Julian C. Baker and Baker Bros. Advisors L.P. may be deemed to be beneficial
owners of the securities directly held by the Baker Funds. Julian C. Baker, Felix J. Baker, Baker Bros. Advisors L.P. and Baker Bros. Advisors (GP) LLC disclaim beneficial ownership of all shares held by the Baker Funds, except to the extent of
their indirect pecuniary interest therein. The business address of Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker and Felix J. Baker is 860 Washington Street, 3rd Floor, New York, NY 10014. The shares of Common Stock
issuable upon conversion of the shares of Series B Preferred Stock held by the Baker Funds are subject to a Beneficial Ownership Limitation of 4.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 902,525 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Atlas Private Holdings (Cayman) Ltd., all of which were issued
in the 2026 Private Placement. Dmitry Balyasny, via intermediate entities, manages Balyasny Asset Management L.P. and has voting and investment control over the securities held by Atlas Private Holdings (Cayman) Ltd. The address for Atlas Private
Holdings (Cayman) Ltd. and Balyasny Asset Management L.P. is 444 West Lake Street, 50th Floor, Chicago, IL 60606. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Atlas Private Holdings (Cayman)
Ltd. are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 722,020 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Cormorant Global Healthcare Master Fund, LP
(&#8220;Cormorant&#8221;), all of which were issued in the 2026 Private Placement. Cormorant Global Healthcare GP, LLC serves as the general partner of Cormorant. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC. Each
of Cormorant Global Healthcare GP, LLC and Ms.&nbsp;Chen disclaim beneficial ownership of such shares except to the extent of any pecuniary interest therein. Ms.&nbsp;Chen, as the managing member of Cormorant Global Healthcare GP, LLC, has sole
voting and investment control over the shares of Common Stock held by Cormorant Global Healthcare Master Fund, LP. The address for Cormorant Global Healthcare Master Fund, LP is 200 Clarendon Street, 52nd Floor, Boston, MA 02116. The shares of
Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Cormorant are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 722,020 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Fairmount Healthcare Fund II LP (&#8220;Fairmount&#8221;), all
of which were issued in the 2026 Private Placement. Fairmount Funds Management LLC </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(&#8220;Fairmount Funds Management&#8221;) serves as investment manager for Fairmount and may be deemed a beneficial owner of any securities of the Company held by Fairmount. Fairmount has
delegated to Fairmount Funds Management the sole power to vote and the sole power to dispose of all securities held in Fairmount&#8217;s portfolio. Because Fairmount has divested itself of voting and investment power over the securities it holds and
may not revoke that delegation on less than 61 days&#8217; notice, Fairmount disclaims beneficial ownership of the securities they hold. As managers of Fairmount Funds Management, Peter Harwin and Tomas Kiselak may be deemed beneficial owners of any
securities of the Company beneficially owned by Fairmount Funds Management. Fairmount Funds Management, Mr.&nbsp;Harwin and Mr.&nbsp;Kiselak disclaim beneficial ownership of securities held by Fairmount, except to the extent of their pecuniary
interest therein. The address for the beneficial owners is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428. The shares of Common Stock issuable upon conversion of the shares of Series&nbsp;B Preferred Stock held by Fairmount are
subject to a Beneficial Ownership Limitation of 4.99%. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 722,020 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Logos Opportunities Fund V LP (&#8220;LOF V&#8221;), all of
which were issued in the 2026 Private Placement. Logos Opportunities V GP LLC (&#8220;GP V&#8221;) is the general partner of Logos Opportunities Fund V LP and may be deemed to have beneficial ownership of these shares. Arsani William and Graham
Walmsley are the members of GP V. Dr. William and Dr. Walmsley disclaim beneficial ownership of these securities except to the extent of each&#8217;s pecuniary interest therein. The address for Logos entities is One Letterman Drive, Building C,
Suite <FONT STYLE="white-space:nowrap">C3-350,</FONT> San Francisco, California 94129. The shares of Common Stock issuable upon conversion of the shares of Series&nbsp;B Preferred Stock held by Logos are subject to a Beneficial Ownership Limitation
of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 722,020 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by RA Capital Healthcare Fund, L.P. (&#8220;RA Capital
Fund&#8221;), all of which were issued in the 2026 Private Placement. RA Capital Management, L.P. serves as an investment manager for RA Capital Fund. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC, of which
Peter Kolchinsky and Rajeev Shah are the managing members. Each such person or entity, as the case may be, has shared voting and/or investment power over the securities held by the Fund and may be deemed the beneficial owner of such shares, and each
such person or entity, as the case may be, disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein and other than for purposes of determining their obligations under Section&nbsp;13(d) of
the Exchange Act. The principal business address of the persons and entities listed above is 200 Berkeley Street, 18th Floor, Boston, MA 02116. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by RA
Capital Fund are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 722,020 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Seligman Healthcare Spectrum (Master) Fund
(&#8220;Seligman&#8221;), all of which were issued in the 2026 Private Placement. Columbia Management Investment Advisers, LLC serves as an investment manager for Seligman. The principal business address of the persons and entities listed above is
c/o Columbia Management Investment Advisors LLC 290 Congress Street, Boston, MA 02210. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Seligman are subject to a Beneficial Ownership Limitation of
9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of (i) 66,240 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Vivo Opportunity Cayman Fund, L.P. (&#8220;Vivo Cayman
Fund&#8221;) and (ii) 655,780 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Vivo Opportunity Fund Holdings, L.P. (&#8220;Vivo Opportunity Fund&#8221; and together with Vivo Cayman Fund, the &#8220;Vivo
Funds&#8221;), all of which were issued in the 2026 Private Placement. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund. Vivo Opportunity </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Cayman, LLC is the general partner of Vivo Cayman Fund. The voting members of each of Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC are Kevin Dai, Gaurav Aggarwal, Frank Kung and Shan
Fu, none of whom has individual voting or investment power with respect to the shares held by Vivo Opportunity Fund Holdings, L.P. or Vivo Opportunity Cayman Fund, L.P. The address of the individuals and entities referenced in this footnote is 192
Lytton Avenue, Palo Alto, California 94301. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the Vivo Funds are subject to a Beneficial Ownership Limitation of 9.99%. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of (i) 314,079&nbsp;shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by ADAR1 Partners, LP (&#8220;ADAR1&#8221;) and
(ii)&nbsp;46,931 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Spearhead Insurance Solutions IDF, LLC&#8212;Series ADAR1 (&#8220;Spearhead&#8221;, and together with ADAR1, the &#8220;ADAR1
Funds&#8221;), all of which were issued in the 2026 Private Placement. The investment manager of ADAR1 and the <FONT STYLE="white-space:nowrap">sub-adviser</FONT> of Spearhead is ADAR1 Capital Management, LLC. The general partner of ADAR1 is ADAR1
Capital Management GP, LLC. The manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC is Daniel Schneeberger. This individual may be deemed to have shared voting and investment power of the shares held by the ADAR1 Funds.
This individual disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. The address for ADAR1 and Daniel Schneeberger is 3503 Wild Cherry Drive, Building 9, Austin, TX 78738. The address for
Spearhead is 3828 Kennett Pike, Suite 202, Greenville, DE 19807. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the ADAR1 Funds are subject to a Beneficial Ownership Limitation of 4.99%.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of (i)&nbsp;361,010&nbsp;shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by B Group Capital LLC issued to B&nbsp;Group
Capital LLC in the 2026 Private Placement and (ii) 249,159 shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by B Group Capital LLC issued to B&nbsp;Group Capital LLC in the Acquisition. Branden B. Muhl
as the manager of B Group Capital LLC has the power to vote and dispose of the securities held by B Group Capital LLC. The principal business address of these persons and entities is 2900 McKinnon St. Suite 1101, Dallas, TX 75201. The shares of
Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by B Group Capital LLC are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; consist of
(i)&nbsp;281,120 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Caligan Partners Master Fund LP (&#8220;Caligan Fund&#8221;), (ii)&nbsp;79,890 shares of Common Stock issuable upon conversion of shares
of Series B Preferred Stock held by certain accounts managed by Caligan (the &#8220;Managed Accounts&#8221;) (iii) 98,343 shares of Common Stock held by Caligan Fund and (iv) 27,659 shares of Common Stock held by the Managed Accounts. The shares
reported under &#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of the 281,120 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Caligan Fund and 79,890 shares of Common
Stock issuable upon conversion of shares of Series B Preferred Stock issued to the Managed Accounts in the 2026 Private Placement. The shares reported under &#8220;Common Stock Beneficially Owned After Offering&#8221; consist of 98,343 shares of
Common Stock held by Caligan Fund and 27,659 shares of Common Stock held by the Managed Accounts. Caligan Partners LP (&#8220;Caligan&#8221;) serves indirectly as the investment manager to the Caligan Fund and the Managed Accounts. David Johnson is
the Managing Partner of Caligan and Managing Member of Caligan Partners GP LLC, the general partner of Caligan, and may be deemed to have voting and investment power over the securities beneficially owned by Caligan and Caligan Fund. The address of
the foregoing entities and person is 780 Third Avenue, 30th Floor, New York, New York 10017. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Caligan Fund and the Managed Accounts are subject to a
Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; consist of
(i)&nbsp;20,999 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Boothbay Diversified Alpha Master Fund LP (&#8220;BBDAMF&#8221;), (ii) 63,584 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Boothbay Absolute
Return Strategies, LP (&#8220;BBARS&#8221;), (iii) 192 shares of Common Stock held by BBDAMF, (iv) 1,083 shares of Common Stock held by BBARS, and does not include the shares of Common Stock reported in Footnote (25). The shares reported under
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of the 20,999 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to BBDAMF and the 63,584 shares of Common Stock issuable
upon conversion of shares of Series B Preferred Stock issued to BBARS in the 2026 Private Placement. The shares reported under &#8220;Common Stock Beneficially Owned After Offering&#8221; consist of 192 shares of Common Stock held by BBDAMF and
1,083 shares of Common Stock held by BBARS. BBARS and BBDAMF are managed by Boothbay Fund Management, LLC (&#8220;Boothbay&#8221;). Boothbay, in its capacity as the investment manager of BBARS and BBDAMF, has delegated to Ikarian Capital, LLC
(&#8220;Ikarian&#8221;), the power to vote and the power to direct the disposition of the shares held by BBDAMF and BBARS. Ari Glass is the Managing Member of Boothbay. Because Boothbay has divested itself of voting and investment power over the
securities it beneficially owns and may not revoke that delegation on less than 61 days&#8217; notice, each of BBARS, BBDAMF, Boothbay and Mr.&nbsp;Glass disclaim beneficial ownership of these securities, except to the extent of any pecuniary
interest therein. Neil Shahrestani is the Chief Executive Officer of Ikarian. The business address of each of the foregoing entities and persons is c/o Ikarian Capital, LLC, 100 Crescent Court, Suite 1620, Dallas, TX 75201. The shares of Common
Stock issuable upon conversion of the shares of Series B Preferred Stock held by BBDAMF and BBARS are subject to a Beneficial Ownership Limitations of 4.99%. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[Reserved.] </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[Reserved.] </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(19)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of (i) 23,357 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by EcoR1 Capital Fund, L.P. (&#8220;EcoR1 Capital Fund&#8221;)
and (ii) 337,653 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by EcoR1 Capital Fund Qualified, L.P. (&#8220;EcoR1 Qualified Fund&#8221;, together with the EcoR1 Capital Fund, the &#8220;EcoR1
Funds&#8221;), all of which were issued in the 2026 Private Placement. EcoR1 Capital, LLC (&#8220;EcoR1&#8221;) is the general partner of the EcoR1 Funds. Oleg Nodelman is the control person of EcoR1 and may be deemed to share dispositive and voting
power over the shares held by the EcoR1 Funds. Mr.&nbsp;Nodelman and EcoR1 both disclaim beneficial ownership of all shares except to the extent of their pecuniary interest therein. The address of the above persons is 357 Tehama Street #3, San
Francisco, CA 94103. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the EcoR1 Funds are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(20)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; consist of
(i)&nbsp;131,940 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Franklin Strategic Series&#8212;Franklin Biotechnology Discovery Fund (&#8220;Franklin Strategic&#8221;), (ii) 229,070 shares of Common
Stock issuable upon conversion of shares of Series B Preferred Stock held by Franklin Templeton Investment Funds&#8212;Franklin Biotechnology Discovery Fund (&#8220;Franklin Templeton&#8221;), (iii)&nbsp;48,771 shares of Common Stock held by
Franklin Strategic and (iv) 84,721 shares of Common Stock held by Franklin Templeton. The shares reported under &#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of the 131,940 shares of Common Stock issuable upon
conversion of shares of Series B Preferred Stock issued to Franklin Strategic in the 2026 Private Placement and the 229,070 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Franklin Templeton in the
2026 Private Placement. The shares reported under &#8220;Common Stock Beneficially Owned After Offering&#8221; consist of 48,771 shares of Common Stock held by Franklin Strategic and 84,721 shares of Common Stock held by Franklin Templeton. Franklin
Advisers, Inc., an SEC registered broker-dealer, is the investment adviser to both Franklin Strategic and Franklin Templeton. Evan McCulloch is the portfolio manager for both Franklin Strategic and Franklin Templeton. Mr.&nbsp;McCulloch may be
deemed to have voting and investment power over the securities held by Franklin Strategic and Franklin Templeton. The address of Franklin Strategic is c/o Franklin Advisers, Inc., One Franklin Parkway, San Mateo, CA 94403. The address of Franklin
Templeton is 8A Rue Albert Borschette, 1246 Kirchberg, Luxembourg. The shares of Common </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Stock issuable upon conversion of the shares of Series B Preferred Stock held by Franklin Strategic and Franklin Templeton are subject to a Beneficial Ownership Limitation of 9.99%.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(21)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 361,010 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Octagon Investments Master Fund LP (&#8220;Octagon&#8221;),
all of which were issued in the 2026 Private Placement. Octagon Capital Advisors LP is the Investment Manager of Octagon Investments Master Fund LP. Ting Jia, Ph.D. is the founder, managing member and Chief Investment Officer of Octagon Capital
Advisors LP. By virtue of such relationships, Dr.&nbsp;Jia and Octagon Capital Advisors LP may be deemed to have voting and investment power of the shares held by Octagon Investments Master Fund LP. Each of Dr.&nbsp;Jia and Octagon Capital Advisors
LP disclaims beneficial ownership of the shares held by Octagon Investments Master Fund LP, except to the extent of his or its pecuniary interest therein, if any. The address for each of Dr.&nbsp;Jia, Octagon Capital Advisors LP and Octagon
Investments Master Fund LP is 654 Madison Avenue, 21st Floor, New York, NY 10065. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Octagon are subject to a Beneficial Ownership Limitation of
9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(22)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 361,010 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by SILV Fund, Ltd. (&#8220;SILV Fund&#8221;), all of which were
issued in the 2026 Private Placement. Sirenia Capital Management LP (&#8220;Sirenia&#8221;) has investment and voting power with respect to the securities held by certain investment funds it manages, including SILV Fund. Sirenia Capital Management
GP LLC (&#8220;Sirenia GP&#8221;) is the general partner of Sirenia. Alex Silverstein is the managing member of Sirenia GP. Each of SILV Fund, Sirenia GP and Mr.&nbsp;Silverstein disclaim beneficial ownership over such securities. The business
address for the individual and entities referenced in this footnote is c/o Sirenia Capital Management LP, 1674 Meridian Avenue, Suite 320, Miami Beach, FL 33139. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred
Stock held by SILV Fund are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(23)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; consist of
(i)&nbsp;361,010 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Trails Edge Biotechnology Master Fund, LP (&#8220;Trails Edge Biotechnology&#8221;) and (ii) 125,000 shares of Common Stock held by Trails
Edge Biotechnology. The shares reported under &#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of the 361,010 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Trails
Edge Biotechnology in the 2026 Private Placement. The shares reported under &#8220;Common Stock Beneficially Owned After Offering&#8221; consist of 125,000 shares of Common Stock held by Trails Edge Biotechnology. Trails Edge Capital Partners, LP
(&#8220;Trails Edge Capital&#8221;) is the investment manager to Trails Edge Biotechnology and may be deemed to beneficially own these securities. Mr.&nbsp;Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and
investment discretion with respect to these securities and as such may be deemed to beneficially own such securities. The address of these funds and persons is 3445 Peachtree Road NE, Atlanta, GA 30326. The shares of Common Stock issuable upon
conversion of the shares of Series B Preferred Stock held by Trails Edge Biotechnology are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(24)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; consist of
361,010 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Woodline Master Fund LP (&#8220;Woodline&#8221;). The shares reported under &#8220;Common Stock That May Be Offered Pursuant to the
Prospectus&#8221; consist of the 361,010 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Woodline in the 2026 Private Placement. Woodline Partners LP serves as the investment manager of Woodline and
may be deemed to be the beneficial owner of the shares. Woodline Partners LP disclaims any beneficial ownership of these shares. The address of Woodline is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111. The shares of Common Stock
issuable upon conversion of the shares of Series B Preferred Stock held by Woodline are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(25)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; consist of
(i)&nbsp;204,225 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Ikarian Healthcare Master Fund, LP (&#8220;Ikarian&#8221;), (ii) 5,076 shares of Common Stock held by Ikarian, and does not include the
shares reported in Footnote (16). The shares reported under &#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of the 204,225 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued
to Ikarian in the 2026 Private Placement. Neil Shahrestani may be deemed to be the beneficial owner of the shares held by Ikarian and disclaims such beneficial ownership of the shares held by Ikarian, except to the extent of his pecuniary interest
therein if any. The address for Ikarian is 100 Crescent Ct., Suite 1620, Dallas, TX 75201. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Ikarian are subject to a Beneficial Ownership Limitation
of 4.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(26)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 180,505 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Boxer Capital Master Fund, LP (&#8220;Boxer Fund&#8221;), all
of which were issued in the 2026 Private Placement. Aaron Davis has voting and dispositive power over the securities held by Boxer Fund. The address of Boxer Fund is 12860 El Camino Real, Ste 300 San Diego, CA 92130. The shares of Common Stock
issuable upon conversion of the shares of Series B Preferred Stock held by Boxer Fund are subject to a Beneficial Ownership Limitation of 4.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(27)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; consist of
(i)&nbsp;150,421 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Marshall Wace Investment Strategies&#8212;Eureka Fund (&#8220;Eureka Fund&#8221;), (ii) 30,084 shares of Common Stock issuable upon
conversion of shares of Series B Preferred Stock held by MW XO Health Innovations Fund II (&#8220;MW XO&#8221;) and (iii) 37,529 shares of Common Stock held by Eureka Fund. The shares reported under &#8220;Common Stock That May Be Offered Pursuant
to the Prospectus&#8221; consist of the 150,421 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Eureka Fund in the 2026 Private Placement and the 30,084 shares of Common Stock issuable upon conversion
of shares of Series B Preferred Stock issued to MW XO in the 2026 Private Placement. The shares reported under &#8220;Common Stock Beneficially Owned After Offering&#8221; consist of 37,529 shares of Common Stock held by the Eureka Fund. Marshall
Wace LLP is the investment manager to the Eureka Fund. Marshall Wace North America L.P. is the investment manager to MW XO. The address of the foregoing entities is George House, 131 Sloane Street, London, SW1X 9AT. The shares of Common Stock
issuable upon conversion of the shares of Series B Preferred Stock held by Eureka Fund and MW XO are subject to a Beneficial Ownership Limitation of 4.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(28)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 144,404 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Affinity Healthcare Fund L.P., all of which were issued in the
2026 Private Placement. Affinity Asset Advisors, LLC is the investment manager of Affinity Healthcare Fund L.P., and Michael Cho may be deemed to indirectly beneficially own the securities directly held by Affinity Healthcare Fund L.P. The address
of Affinity Healthcare Fund L.P., Affinity Asset Advisors, LLC and Mr.&nbsp;Cho is 450 Park Avenue, Suite 1403, New York, NY 10022. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Affinity
Healthcare Fund L.P. are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(29)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 144,404 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Alyeska Master Fund, L.P. (&#8220;Alyeska Master Fund&#8221;),
all of which were issued in the 2026 Private Placement. Alyeska Investment Group, L.P., the investment manager of Alyeska Master Fund (the &#8220;Selling Securityholder&#8221;), has voting and investment control of the shares held by the Selling
Securityholder. Anand Parekh is the Chief Executive Officer of Alyeska Investment Group, L.P. and may be deemed to be the beneficial owner of such shares. Mr.&nbsp;Parekh, however, disclaims any beneficial ownership of the shares held by the Selling
Securityholder. The registered address of Alyeska Master Fund, L.P. is at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, South Church Street George Town, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1104,</FONT> Cayman
Islands. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Alyeska Investment Group, L.P. is located at 77 W. Wacker, Suite 700, Chicago IL 60601. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the
Alyeska Master Fund, L.P. are subject to a Beneficial Ownership Limitation of 9.99%. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(30)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; consist of
(i)&nbsp;18,050 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Special Situations Life Sciences Fund, L.P. (&#8220;SS Life Sciences&#8221;), (ii) 41,929 shares of Common Stock issuable upon conversion
of shares of Series B Preferred Stock held by Special Situations Fund III QP, L.P. (&#8220;SS QP&#8221;), (iii)&nbsp;12,222 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Special Situations Cayman Fund,
L.P. (&#8220;SS Cayman&#8221; and, together with SS Life Sciences and SS QP, the &#8220;Special Situations Funds&#8221;), (iv) 211 shares of Common Stock held by SS Life Sciences, (v)&nbsp;487 shares of Common Stock held by SS QP and (vi) 145 shares
of Common Stock held by SS Cayman. The shares reported under &#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of the 18,050 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued
to SS Life Sciences in the 2026 Private Placement, the 41,929 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to SS QP in the 2026 Private Placement and the 12,222 shares of Common Stock issuable upon
conversion of shares of Series B Preferred Stock issued to SS Cayman in the 2026 Private Placement. The shares reported under &#8220;Common Stock Beneficially Owned After Offering&#8221; consist of 211 shares of Common Stock held by SS Life
Sciences, 487 shares of Common Stock held by SS QP and 145 shares of Common Stock held by SS Cayman. A WM Investment Company, Inc. (&#8220;A WM&#8221;) is the investment adviser to each of the Special Situations Funds. David Greenhouse and Adam
Stettner are the principal owners of A WM. Through their control of A WM, Messrs. Greenhouse and Stettner share voting and investment control over the portfolio securities of each of the Special Situations Funds. Messrs. Greenhouse and Stettner
disclaim any beneficial ownership of the reported shares other than to the extent of any pecuniary interest each of them may have therein. The address of AWM, each of the Special Situations Funds and Messrs. Greenhouse and Stettner is 527 Madison
Avenue, Suite 2600, New York, NY 10022. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the Special Situations Funds are subject to a Beneficial Ownership Limitation of 9.99%.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(31)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 72,201 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Squadron Master Fund LP, all of which were issued in the 2026
Private Placement. Squadron Capital Management LLC serves as investment adviser to Squadron Master Fund LP and may be deemed to be the beneficial owner of all securities held by the fund. Matthew Sesterhenn and William F. Blank III, as Partners of
Squadron Capital Management LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all securities held by the funds. Squadron Capital Management LLC and Messrs. Sesterhenn and Blank disclaim
beneficial ownership over any of the securities. The address of Squadron Capital Management LLC is 999 Oakmont Plaza Drive, Suite 600, Westmont, IL 60559. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock
held by Squadron Master Fund LP are subject to a Beneficial Ownership Limitation of 9.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(32)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 9,176 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Able Partners NYC, LLC (&#8220;Able Partners&#8221;), all of
which were issued in the Acquisition. Lisa Blau may be deemed to be beneficial owner of securities held by Able Partners. The address for Able Partners is 30 Hudson Yards, FL 72, New York, NY 10001. The shares of Common Stock issuable upon
conversion of the shares of Series B Preferred Stock held by Able Partners are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(33)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of (i) 1,861 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by AgFunder Fund IV, L.P. (&#8220;AgFunder IV&#8221;) and (ii)
2,287 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by AgFunder <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Fund III, A Series of AgFunder Master Fund, LLC (&#8220;AgFunder <FONT
STYLE="white-space:nowrap">Co-Investment&#8221;),</FONT> all of which were issued in the Acquisition. Donald Rob Leclerc may be deemed to have </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
investment discretion and voting power over the shares held by the AgFunder IV and AgFunder <FONT STYLE="white-space:nowrap">Co-Investment.</FONT> The address for AgFunder IV and AgFunder <FONT
STYLE="white-space:nowrap">Co-Investment</FONT> is 595 Pacific Ave, 4th Floor, San Francisco, CA 94133. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by AgFunder IV and AgFunder <FONT
STYLE="white-space:nowrap">Co-Investment</FONT> each are subject to a Beneficial Ownership Limitation of 19.99%. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(34)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 62,264 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Alpha Capital Corp., all of which were issued in the
Acquisition. Jaime Javier Montealegre may be deemed to be beneficial owner of securities held by Alpha Capital Corp. The address for Alpha Capital Corp. is c/o Fox Horan&nbsp;&amp; Camerini LLP (RUB/ABF) 885 Third Avenue, Floor 17, New York, NY
10022. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Alpha Capital Corp. are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(35)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; consist of
(i)&nbsp;761,428 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Anand Parikh and (ii) 42,933 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2026.
The shares reported under &#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of the 761,428&nbsp;shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Mr.&nbsp;Parikh in the
Acquisition. The shares reported under &#8220;Common Stock Beneficially Owned After Offering&#8221; consist of 42,933 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2026. The shares of Common
Stock issuable upon conversion of the shares of Series B Preferred Stock held by Mr.&nbsp;Parikh are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(36)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 18,679 shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Angelle Advisors LLC, all of which were issued in the
Acquisition. Chris Wang serves as the controlling person of Angelle Advisors LLC and may be deemed to have investment discretion and voting power over the shares held by Angelle Advisors LLC. The address for Angelle Advisors LLC is 5348 Vegas Drive,
Suite 947, Las Vegas, NV 89108. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Angelle Advisors LLC are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(37)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 12,453 shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Anne C. Harrison, all of which were issued in the
Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Anne C. Harrison are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(38)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 18,352 shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Apple Island Investment Fund I LLC (&#8220;Apple
Island&#8221;), all of which were issued in the Acquisition. Sachin Gupta serves as the controlling person of Apple Island and may be deemed to have investment discretion and voting power over the shares held by Apple Island. The address for Apple
Island is 820 S. Washington, Hinsdale, IL 60521. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Apple Island are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(39)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 13,698 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Bar Investments LLC, all of which were issued in the
Acquisition. Prashanth Reddy serves as the controlling person of Bar Investments LLC and may be deemed to have investment discretion and voting power over the shares held by Bar Investments LLC. The address for Bar Investments LLC is 700 E Ogden,
Suite 305, Westmont, IL 60559. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Bar Investments LLC are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(40)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 79,731 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Benjamin D. Hopkins, all of which were issued in the
Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Benjamin D. Hopkins are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(41)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 4,980 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Burnett F. King, all of which were issued in the Acquisition.
The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Burnett F. King are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(42)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of (i) 26,577 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Cantley GRAT Remainder Trust f/b/o Alexandra Cantley u/d/t
7/1/16 (&#8220;A. Cantley Trust&#8221;) and (ii) 26,577 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Cantley GRAT Remainder Trust f/b/o Mariko Cantley u/d/t 7/1/16 (&#8220;M. Cantley Trust&#8221;),
all of which were issued in the Acquisition. Vicki Sato may be deemed to have investment discretion and voting power over the shares held by the A. Cantley Trust and the M. Cantley Trust. The shares of Common Stock issuable upon conversion of the
shares of Series B Preferred Stock held by the A. Cantley Trust and the M. Cantley Trust are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(43)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consists of (i) 18,608 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Cantos Ivy, L.L.C. (&#8220;Cantos Ivy&#8221;), (ii)
118,207 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Cantos Ventures III, L.P. (&#8220;Cantos Ventures&#8221;) and (iii) 8,737 shares of Common Stock issuable upon conversion of shares of Series B
Preferred Stock held by FA Fund I, a series of Cantos Ventures Funds, LP (&#8220;FA Fund&#8221;), all of which were issued in the Acquisition. Julian Rountree may be deemed to have investment discretion and voting power over the shares held by
Cantos Ivy, Cantos Ventures and FA Fund. The address for Cantos Ivy and Cantos Ventures is 595 Pacific Ave, 4th Floor, San Francisco, CA 94133. The address for FA Fund is PO Box 3217, Seattle, WA 98114. The shares of Common Stock issuable upon
conversion of the shares of Series B Preferred Stock held by Cantos Ivy, Cantos Ventures and FA Fund are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(44)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of (i) 18,608 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Consolidated Investments International, LLC Series B
(&#8220;Consolidated Investments Series B&#8221;) and (ii) 124,527 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Consolidated Investments International, LLC Series G (&#8220;Consolidated Investments
Series G&#8221;), all of which were issued in the Acquisition. Robert Granieri serves as the sole member of each of Consolidated Investments Series B and Consolidated Investments Series G and may be deemed to have investment discretion and voting
power over the shares held by Consolidated Investments Series B and Consolidated Investments Series G. The address for Consolidated Investments Series B and Consolidated Investments Series G is 500 Mamaroneck Avenue, Suite 301, Harrison, NY 10528.
The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Consolidated Investments Series B and Consolidated Investments Series G are subject to a Beneficial Ownership Limitation of 19.99%.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(45)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 2,972 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Daniel J. Conway, all of which were issued in the Acquisition.
The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Daniel J. Conway are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(46)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 156,669 shares of Common Stock issuable </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
upon conversion of shares of Series B Preferred Stock held by Debbie Chirnomas, all of which were issued in the Acquisition. The shares of Common Stock issuable upon conversion of the shares of
Series B Preferred Stock held by Debbie Chirnomas are subject to a Beneficial Ownership Limitation of 19.99%. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(47)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; consist of
(i)&nbsp;1,016 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Domen Kampjut and (ii) 1,594 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2026.
The shares reported under &#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of the 1,016 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Domen Kampjut in the
Acquisition. The shares reported under &#8220;Common Stock Beneficially Owned After Offering&#8221; consist of 1,594 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2026. The shares of Common
Stock issuable upon conversion of the shares of Series B Preferred Stock held by Domen Kampjut are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(48)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 27,262 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by <FONT STYLE="white-space:nowrap">FA-0611</FONT> Fund I, a
series of Umami Capital, LP <FONT STYLE="white-space:nowrap">(&#8220;FA-0611&#8221;),</FONT> all of which were issued in the Acquisition. James Lu Morrissey serves as the controlling person of <FONT STYLE="white-space:nowrap">FA-0611</FONT> and may
be deemed to have investment discretion and voting power over the shares held by <FONT STYLE="white-space:nowrap">FA-0611.</FONT> Mr.&nbsp;Morrissey disclaims beneficial ownership of these shares. The address for
<FONT STYLE="white-space:nowrap">FA-0611</FONT> is PO Box 3217, Seattle, WA 98114. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by <FONT STYLE="white-space:nowrap">FA-0611</FONT> are subject to a
Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(49)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 124,527 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Faeth Investments, LLC, all of which were issued in the
Acquisition. Rodney H. Thomas may be deemed to be beneficial owner of securities held by Faeth Investments, LLC. The address for Faeth Investments, LLC is 12647 Olive Blvd, Ste. 510, St. Louis, MO 63141. The shares of Common Stock issuable upon
conversion of the shares of Series B Preferred Stock held by Faeth Investments, LLC are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(50)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 39,849 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by the Felix Gurevich 2023 Family Trust (the &#8220;Gurevich
Trust&#8221;), all of which were issued in the Acquisition. Does not include the shares reported in Footnote (67). Felix Gurevich serves as the controlling person of the Gurevich Trust and may be deemed to have investment discretion and voting power
over the shares held by the Gurevich Trust. The address for the Gurevich Trust is 17305 Ponte Chiasso Dr., Boca Raton, FL 33496. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the Gurevich Trust
are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(51)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 249,053 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Fund I, a series of Avicella Capital Fund, LP (&#8220;Avicella
Fund I&#8221;), all of which were issued in the Acquisition. Gennady Bratslavsky serves as the controlling person of Avicella Fund I and may be deemed to have investment discretion and voting power over the shares held by Avicella Fund I.
Mr.&nbsp;Bratslavsky disclaims beneficial ownership of these shares. The address for Fund I is PO Box 3217, Seattle, WA 98114. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Avicella Fund I are
subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(52)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of (i) 955,468 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Future Ventures L.P. (&#8220;Future Ventures&#8221;) and
(ii) 60,987 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Future Ventures Side Fund, L.P. (&#8220;Future Side Fund&#8221;), all of which were issued in
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the Acquisition. Steve Jurvetson and Maryanna Saenko serve as the controlling persons of Future Ventures and Future Side Fund and may be deemed to have investment discretion and voting power over
the shares held by Future Ventures and Future Side Fund. The address for Future Ventures and Future Side Fund is 465 First Street, Los Altos, CA 94022. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock
held by Future Ventures and Future Side Fund are subject to a Beneficial Ownership Limitation of 19.99%. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(53)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 94 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Georgina F. Steele, all of which were issued in the Acquisition.
The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Georgina F. Steele are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(54)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 79,731 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Greg Hannon, all of which were issued in the Acquisition. The
shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Mr.&nbsp;Hannon are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(55)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 13,516 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Greg Mork, all of which were issued in the Acquisition. The
shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Mr.&nbsp;Mork are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(56)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of (i) 32,227 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by iSelect Qualified Purchaser Fund, LLC (&#8220;iSelect
Purchaser&#8221;) and (ii) 13,330 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by iSelect Innovation Fund (B)&nbsp;I, LLC (&#8220;iSelect Innovation&#8221;), all of which were issued in the Acquisition.
James Carter Williams serves as the controlling person of iSelect Purchaser and iSelect Innovation and may be deemed to have investment discretion and voting power over the shares held by iSelect Purchaser and iSelect Innovation. The address for
iSelect Purchaser and iSelect Innovation is 7750 Maryland Avenue, Box 11826, St. Louis, MO 63105. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by iSelect Purchaser and iSelect Innovation are
subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(57)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 3,320 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Javier Piggee, all of which were issued in the Acquisition. The
shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Mr.&nbsp;Piggee are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(58)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 44,763 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Jayson Dallas, all of which were issued in the Acquisition. The
shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Mr.&nbsp;Dallas are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(59)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; consists of
(i)&nbsp;100&nbsp;shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by H. Jonathan G. Lindstr&ouml;m and (ii) 3,321 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of
March&nbsp;31, 2026. The shares reported under &#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of the 100&nbsp;shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to
Mr.&nbsp;Lindstr&ouml;m in the Acquisition. The shares reported under &#8220;Common Stock Beneficially Owned After Offering&#8221; consist of 3,321 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of
March&nbsp;31, 2026. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Mr.&nbsp;Lindstr&ouml;m are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(60)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 79,731 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Karen H. Vousden, all of which were issued in the Acquisition.
The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Karen H. Vousden are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(61)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 623 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Katelyn M. Patterson, all of which were issued in the Acquisition.
The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Katelyn M. Patterson are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(62)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 114,885 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by KdT Ventures Fund II, LP (&#8220;KdT Ventures&#8221;), all of
which were issued in the Acquisition. Mack Healy may be deemed to be beneficial owner of securities held by KdT Ventures. The address for KdT Ventures is 910 Juniper St., Austin, TX 78702. The shares of Common Stock issuable upon conversion of the
shares of Series B Preferred Stock held by KdT Ventures are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(63)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consists of (i) 988,883 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Khosla Ventures Series D, LP (&#8220;KV Seed D LP&#8221;)
and (ii) 1,643,349 shares of Common Stock issuable upon conversion of Series B Preferred Stock held by Khosla Ventures VI, LP (&#8220;KV VI LP&#8221;, and, together with KV Seed D LP, &#8220;Khosla Ventures&#8221;), all of which were issued in the
Acquisition. Khosla Ventures Seed Associates D, LLC (&#8220;KV Seed D GP&#8221;) is the general partner of KV Seed D LP. Khosla Ventures Associates VI, LLC (&#8220;KV VI GP&#8221;) is the general partner of KV VI LP. Vinod Khosla is the managing
member of VK Services, LLC (&#8220;VK Services&#8221;), which is the sole manager of each of KV Seed GP and KV VI GP. Each of KV Seed D GP, VK Services and Vinod Khosla may be deemed to possess voting and investment control over such securities held
by KV Seed D LP, and each of KV Seed D GP, VK Services, and Vinod Khosla may be deemed to have indirect beneficial ownership of such securities held by KV Seed D LP. Each of KV VI GP, VK Services and Vinod Khosla may be deemed to possess voting and
investment control over such securities held by KV VI LP, and each of KV VI GP, VK Services, and Vinod Khosla may be deemed to have indirect beneficial ownership of such securities held by KV VI LP. Each reporting person disclaims beneficial
ownership of such shares except to the extent of his or its pecuniary interests therein. The address for each entity is 2128 Sand Hill Road, Menlo Park, CA 94025. The shares of Common Stock issuable upon conversion of the shares of Series B
Preferred Stock held by Khosla Ventures are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(64)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consists of 26,578 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Lewis Cantley, all of which were issued in the Acquisition.
The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Lewis Cantley are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(65)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 79,731 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Marcus Goncalves, all of which were issued in the Acquisition.
The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Marcus Goncalves are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(66)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 18,679 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Margao II, LP (&#8220;Margao II&#8221;), all of which were
issued in the Acquisition. Mark Britto may be deemed to be beneficial owner of securities held by Margao II. The address for Margao is 2800 Warren St., Austin, TX 78703. The shares of Common Stock
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
issuable upon conversion of the shares of Series B Preferred Stock held by Margao II are subject to a Beneficial Ownership Limitation of 19.99%. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(67)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 59,773 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by the Marina Sheyfer 2023 Family Trust (the &#8220;Sheyfer
Trust&#8221;), all of which were issued in the Acquisition. Does not include the shares reported in Footnote (50). Felix Gurevich serves as the controlling person of the Sheyfer Trust and may be deemed to have investment discretion and voting power
over the shares held by the Sheyfer Trust. The address for the Sheyfer Trust is 17305 Ponte Chiasso Dr., Boca Raton, FL 33496. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the Sheyfer Trust
are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(68)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 223,818 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Mars Health Fund I, LLC (&#8220;Mars&#8221;), all of which
were issued in the Acquisition. Geoffrey W. Smith may be deemed to be beneficial owner of securities held by Mars. The address for Mars is 11 Times Square, Suite 1500A, New York, NY 10036. The shares of Common Stock issuable upon conversion of the
shares of Series B Preferred Stock held by Mars are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(69)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 458,927 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Oliver D.K. Maddocks, all of which were issued in the
Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Oliver D.K. Maddocks are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(70)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; consists of
(i)&nbsp;1,862 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Petros A. Tyrakis and (ii) 4,273 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of March&nbsp;31,
2026. The shares reported under &#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of the 1,862 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock issued to Petros A. Tyrakis in the
Acquisition. The shares reported under &#8220;Common Stock Beneficially Owned After Offering&#8221; consist of 4,273 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of March&nbsp;31, 2026. The shares of Common
Stock issuable upon conversion of the shares of Series B Preferred Stock held by Petros A. Tyrakis are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(71)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 27,783 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Robert Gould, all of which were issued in the Acquisition. The
shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Robert Gould are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(72)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 262 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Ryan O&#8217;Connor, all of which were issued in the Acquisition.
The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Ryan O&#8217;Connor are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(73)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 14,237 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Ryan W. Whitney, all of which were issued in the Acquisition.
The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Ryan W. Whitney are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(74)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 2,919,672 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by S2G Builders Food&nbsp;&amp; Agriculture
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Fund III, LP (&#8220;S2G Fund&#8221;), all of which were issued in the Acquisition. S2G Investments, LLC (&#8220;S2G Investments&#8221;) is a registered investment advisor to S2G Fund and may be
deemed to have investment discretion and voting power over the shares held by S2G Fund. The address for S2G Fund and S2G Investments is 210 N. Carpenter Street, Suite 800, Chicago, IL 60607. The shares of Common Stock issuable upon conversion of the
shares of Series B Preferred Stock held by S2G Fund are subject to a Beneficial Ownership Limitation of 9.99%. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(75)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 18,352 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by S3 Partners Group, LLLP (&#8220;S3 Partners&#8221;), all of
which were issued in the Acquisition. J. Brock Saunders may be deemed to be beneficial owner of securities held by S3 Partners. The address for S3 Partners is 5605 Grove Ave., Richmond, VA 23226. The shares of Common Stock issuable upon conversion
of the shares of Series B Preferred Stock held by S3 Partners are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(76)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 79,731 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Scott W. Lowe, all of which were issued in the Acquisition. The
shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Scott W. Lowe are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(77)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 119,597 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Siddhartha Mukherjee, all of which were issued in the
Acquisition. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Siddhartha Mukherjee are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(78)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 79,731 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Simon R.V. Knott, all of which were issued in the Acquisition.
The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Simon R.V. Knott are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(79)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 44,763 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Stephen M. Hahn, all of which were issued in the Acquisition.
The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Stephen M. Hahn are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(80)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 7,915 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Todd A. Young, all of which were issued in the Acquisition. The
shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by Todd A. Young are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(81)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of (i) 2,280 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Unshackled Ventures Fund II, LP (&#8220;Unshackled Ventures
II&#8221;), (ii) 1,226 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Unshackled Ventures Fund <FONT STYLE="white-space:nowrap">II-A,</FONT> LP (&#8220;Unshackled Fund
<FONT STYLE="white-space:nowrap">II-A&#8221;),</FONT> (iii)&nbsp;24,906 shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Unshackled Syndicate 2018, LLC (&#8220;Unshackled Syndicate&#8221;) and (iv) 7,444
shares of Common Stock issuable upon conversion of shares of Series B Preferred Stock held by Unshackled Syndicate 2018 LLC (Class <FONT STYLE="white-space:nowrap">E-</FONT> Faeth) (&#8220;Unshackled Syndicate Class&nbsp;E&#8221;, and together with
Unshackled Ventures II, Unshackled Ventures <FONT STYLE="white-space:nowrap">II-A,</FONT> and Unshackled Syndicate, the &#8220;Unshackled Funds&#8221;), all of which were issued in the Acquisition. ANAR Management, LLC. serves as an investment
manager for Unshackled Funds, of which Manan Mehta and Nitin Pachisia are the controlling persons. Each such person may be deemed as the beneficial owner of such shares, and each such person, disclaims beneficial ownership of such securities except
to the extent of their respective pecuniary interest therein and other than for purposes of determining their obligations under Section&nbsp;13(d) of the Exchange Act. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
The address for the Unshackled Funds is 831 Santa Maria Way, Lafayette, CA 94549. The shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock held by the
Unshackled Funds are subject to a Beneficial Ownership Limitation of 19.99%. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(82)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#8220;Shares of Common Stock Beneficially Owned Prior to Offering&#8221; and
&#8220;Common Stock That May Be Offered Pursuant to the Prospectus&#8221; consist of 2,102 shares of Common Stock issuable upon exercise of the Warrant held by Western Alliance Bancorp (&#8220;Western Alliance&#8221;) to purchase shares of Series B
Preferred Stock, which will be exercisable for shares of Common Stock upon conversion of the shares of Series B Preferred Stock. The Warrant was assumed by the Company in the Acquisition. The address for Western Alliance is One E. Washington, Suite
1400, Phoenix, AZ 85004. The shares of Common Stock underlying the shares of Series B Preferred Stock issuable upon exercise of the Warrant held by Western Alliance are subject to a Beneficial Ownership Limitation of 19.99%. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Material Relationships with the Selling Stockholders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following Selling Stockholders have or previously had the below material relationships with us or Faeth within the past three years: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Following the Acquisition, Anand Parikh was appointed as our Chief Operating Officer. In addition,
Mr.&nbsp;Parikh is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Faeth and previously served as the Chief Executive Officer and a director of Faeth Subsidiary from April 2019 until the closing of the Acquisition. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oliver Maddocks is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Faeth has served as the Chief
Scientific Officer of Faeth Subsidiary since April 2019. In addition, Mr.&nbsp;Maddocks previously served as a director of Faeth Subsidiary from April 2019 until the closing of the Acquisition. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Debbie Chirnomas has served as the Chief Medical Officer of Faeth Subsidiary since May 2023.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Each of Benjamin D. Hopkins, Greg Hannon, Marcus Goncalves, Lewis Cantley, Karen Vousden, Siddhartha Mukherjee
and Scott W. Lowe is a scientific <FONT STYLE="white-space:nowrap">co-founder</FONT> of Faeth. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We expect that Karen Vousden will be appointed as a member of our board of directors following the receipt of
stockholder approval of the Required Company Stockholder Matters. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stephen M. Hahn previously served as a director of Faeth Subsidiary from September 2024 until the closing of the
Acquisition. In addition, we expect that Mr.&nbsp;Hahn will be appointed as a member of our board of directors following the receipt of stockholder approval of the Required Company Stockholder Matters. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jayson Dallas previously served as a director of Faeth Subsidiary from June 2024 until the closing of the
Acquisition. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Robert Gould previously served as a director of Faeth Subsidiary from July 2021 until the closing of the
Acquisition. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A designee of Khosla Ventures previously served on the board of directors of Faeth Subsidiary from June 2019
until the closing of the Acquisition pursuant to Khosla Ventures&#8217; previously held right to designate a director to the board of directors of Faeth Subsidiary. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A designee of S2G Fund previously served on the board of directors of Faeth Subsidiary from March 2022 until June
2024 pursuant to S2G Fund&#8217;s previously held right to designate a director to the board of directors of Faeth Subsidiary. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ryan W. Whitney previously served as the Chief of Staff and VP and Head of Finance, Operations of Faeth
Subsidiary from January 2020 to June 2025. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Acquisition Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section titled &#8220;Prospectus Summary&#8212;Recent Developments&#8221; for a description of the terms of the agreements entered into
in connection with the Acquisition Transactions which is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc133316_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders, which as used herein includes donees, pledgees, transferees or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">other&nbsp;successors-in-interest&nbsp;selling</FONT></FONT> Resale Shares or interests in Resale Shares received after the date of this prospectus from a Selling Stockholder as a gift, pledge, partnership distribution or
other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their Resale Shares or interests in Resale Shares on any stock exchange, market or trading facility on which the shares are traded or in private
transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may use any one or more of the following methods when disposing of Resale Shares or interests therein: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales and settlement of short sales; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may, from time to time, pledge or grant a security interest in some or all of the Resale Shares owned by them and, if
they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Resale Shares, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other
applicable provision of the Securities Act, amending the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling Stockholders under this prospectus. The Selling Stockholders also may transfer the
Resale Shares in other circumstances, in which case the transferees, pledgees or other successors in interest will be the Selling Stockholders for purposes of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of Resale Shares or interests therein, the Selling Stockholders may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of Common Stock in the course of hedging the positions they assume. The Selling Stockholders may also sell Resale Shares short and deliver these securities to
close out their short positions, or loan or pledge the Resale Shares to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial
institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the Selling
Stockholders from the sale of the Resale Shares offered by them will be the purchase price of the Resale Shares less discounts or commissions, if any. Each of the Selling </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of Resale Shares to be made directly or through
agents. We will not receive any of the proceeds from this offering. If the Warrant is exercised for cash, we will receive the net proceeds therefrom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders also may resell all or a portion of the Resale Shares in open market transactions in reliance upon Rule 144 under the
Securities Act, provided that they meet the criteria and conform to the requirements of that rule, or another available exemption from the registration requirements under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders and any underwriters, broker-dealers or agents that participate in the sale of the Resale Shares or interests therein
may be &#8220;underwriters&#8221; within the meaning of Section&nbsp;2(a)(11) of the Securities Act (it being understood that the Selling Stockholders shall not be deemed to be underwriters solely as a result of their participation in this
offering). Any discounts, commissions, concessions or profit they earn on any resale of the Resale Shares may be underwriting discounts and commissions under the Securities Act. Selling Stockholders who are &#8220;underwriters&#8221; within the
meaning of Section&nbsp;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To
the extent required, the Resale Shares to be sold, the names of the Selling Stockholders, the respective purchase prices and public offering prices, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with
respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of some states, if applicable, the Resale Shares may be sold in these jurisdictions only through
registered or licensed brokers or dealers. In addition, in some states the Resale Shares may not be sold unless they have been registered or qualified for sale or an exemption from registration or qualification requirements is available and is
complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the Selling Stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply
to sales of shares in the market and to the activities of the Selling Stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available
to the Selling Stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Selling Stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the Resale Shares
against certain liabilities, including liabilities arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the Selling Stockholders
against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the Resale Shares offered by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed with the Selling Stockholders to use commercially reasonable efforts to cause the registration statement of which this
prospectus constitutes a part to become effective and to remain continuously effective until the earlier of: (i)&nbsp;the date on which the Selling Stockholders shall have resold or otherwise disposed of all the Resale Shares covered by this
prospectus and (ii)&nbsp;the date on which the Resale Shares covered by this prospectus no longer constitute &#8220;Registrable Securities&#8221; as such term is defined in the RRA, such that they may be resold by the Selling Stockholders without
registration and without regard to any volume <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">or&nbsp;manner-of-sale&nbsp;limitations</FONT></FONT> and without current public information pursuant to Rule 144 under the Securities
Act or any other rule of similar effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that any Selling Stockholder will sell any or all of the Resale Shares
registered pursuant to the registration statement of which this prospectus forms a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc133316_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal matters, including the legality of the securities offered, will be passed upon for us by Cooley LLP, Washington, D.C. Additional
legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc133316_9"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Sensei Biotherapeutics, Inc. and Faeth Therapeutics, Inc. incorporated by reference in this Registration Statement
have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their reports. Such financial statements are incorporated by reference in reliance upon the reports of such firm, given their
authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc133316_10"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the informational requirements of the Exchange Act and are required to file annual, quarterly and other reports, proxy
statements and other information with the SEC. The SEC maintains an Internet site (http://www.sec.gov) that contains reports, proxy and information statements, and various other information about us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about us is also available at our website at www.senseibio.com. However, the information on, or that can be accessed through, our
website is not a part of this prospectus and is not incorporated by reference into this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc133316_11"></A>INCORPORATION OF INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#8220;incorporate by reference&#8221; information that we file with the SEC, which means that we can disclose important
information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information we file later with the SEC will automatically update and supersede this information. A
Current Report (or portion thereof) furnished, but not filed, on Form <FONT STYLE="white-space:nowrap">8-K</FONT> shall not be incorporated by reference into this prospectus. We incorporate by reference the documents listed below and any future
filings we make with the SEC under Section&nbsp;13(a), 13(c), 14, or 15(d) of the Exchange Act, including all filings made after the date of the filing of this registration statement and prior to the effectiveness of this registration statement,
except, in each case, as to any portion of any future report or document that is not deemed filed under such provisions, prior to the termination of any offering of securities made by this prospectus: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2025, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001829802/000119312526132014/snse-20251231.htm">March<U></U>&nbsp;30, 2026</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Definitive Proxy Statement on Schedule 14A for our Annual Meeting filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1829802/000119312526182143/d16802ddef14a.htm">April&nbsp;27,
 2026</A> (except for information contained therein which is furnished rather than filed); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (except for information contained therein
which is furnished rather than filed) filed on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001829802/000119312526051815/d82134d8k.htm">February<U></U>&nbsp;
13, 2026</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001829802/000119312526056135/d112826d8k.htm">February<U></U>&nbsp;
18, 2026</A> (as amended on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001829802/000119312526157038/d40329d8ka.htm">April<U></U>&nbsp;
15, 2026</A>), and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001829802/000119312526158951/d85136d8k.htm">April<U></U>&nbsp;16, 2026</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our Common Stock which is registered under Section&nbsp;12 of the Exchange Act, described
in&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1829802/000119312526132014/snse-ex4_1.htm">Exhibit 4.1</A> to our Annual Report for the fiscal year ended December&nbsp;31, 2025, filed with the SEC on March&nbsp;30, 2026, including all
amendments or reports filed for the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish without charge to you, on
written or oral request, a copy of any or all of such documents that has been incorporated herein by reference (other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this
prospectus incorporates). Written or oral requests for copies should be directed to Sensei Biotherapeutics, Inc., Attn: Investor Relations, 1405 Research Boulevard, Suite 125, Rockville, MD 20850, telephone number (240) <FONT
STYLE="white-space:nowrap">243-8000.</FONT> See the section of this prospectus entitled &#8220;Where You Can Find More Information&#8221; for information concerning how to read and obtain copies of materials that we file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in this prospectus, or in a document all or a portion of which is incorporated by reference, shall be modified or
superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or
superseded shall not, except as so modified or superseded, constitute a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Expenses of Issuance and Distribution </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expenses payable by us in connection with the issuance and distribution of the securities being registered hereunder on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (other than underwriting discounts and commissions, if any) are set forth below. The Selling Stockholders will not bear any portion of such expenses. Each item listed is estimated, except for the SEC
registration fee: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,080.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">567,080.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Officers and Directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of the State of Delaware. Section&nbsp;102 of the Delaware General Corporation Law permits a corporation to
eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good
faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee
or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlements actually and reasonably
incurred by the person in connection with an action, suit or proceeding to which he is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed
to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification
shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite
the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by the Delaware General Corporation Law, our certificate of incorporation and bylaws provide that: (i)&nbsp;we are required to
indemnify our directors to the fullest extent permitted by the Delaware General Corporation Law; (ii)&nbsp;we may, in our discretion, indemnify our officers, employees and agents as set forth in the Delaware General Corporation Law; (iii)&nbsp;we
are required, upon satisfaction of certain conditions, to advance all expenses incurred by our directors in connection with certain legal proceedings; (iv)&nbsp;the rights conferred in the bylaws are not exclusive; and (v)&nbsp;we are authorized to
enter into indemnification agreements with our directors, officers, employees and agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements
with each of our directors and executive officers that require us to indemnify them against expenses, judgments, fines, settlements and other amounts that any such person becomes legally obligated to pay (including with respect to a derivative
action) in connection with any proceeding, whether actual or threatened, to which such person may be made a party by reason of the fact that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such person is or was a director or officer of us or any of our affiliates, provided such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to,
our best interests. The indemnification agreements also set forth certain procedures that apply in the event of a claim for indemnification thereunder. At present, no litigation or proceeding is pending that involves any of our directors or officers
regarding which indemnification is sought, nor are we aware of any threatened litigation that may result in claims for indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a directors&#8217; and officers&#8217; liability insurance policy. The policy insures directors and officers against unindemnified
losses arising from certain wrongful acts in their capacities as directors and officers and reimburses us for those losses for which we have lawfully indemnified the directors and officers. The policy contains various exclusions. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;2.1&#135;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1829802/000119312526056135/d112826dex21.htm">Agreement and Plan of Merger, dated February&nbsp;
17, 2026, by and among Sensei Biotherapeutics, Inc., Sapphire First Merger Sub, Inc., Sapphire Second Merger Sub, LLC, Faeth Holdings Therapeutics, Inc. and Faeth Therapeutics, LLC (incorporated by reference to Exhibit 2.1 to the Registrant&#8217;s Current
 Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39980),</FONT> filed with the SEC on February&nbsp;18, 2026).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1829802/000119312521037280/d95909dex31.htm">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39980),</FONT> filed with the SEC on February 11, 2021).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1829802/000119312525140329/d945713dex31.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Sensei Biotherapeutics, Inc., effective June<U></U>&nbsp;
16, 2025 (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File No.<U></U><FONT STYLE="white-space:nowrap">&nbsp;
001-39980),</FONT> filed with the SEC on June<U></U>&nbsp;13, 2025). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1829802/000119312522301836/d514100dex31.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39980),</FONT> filed with the SEC on December&nbsp;9, 2022).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1829802/000119312523063093/d470819dex31.htm">Certificate of Designations of the Series A Junior Participating Cumulative Preferred Stock of the Registrant (incorporated by reference to Exhibit
3.1 to the Registrant&#8217;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39980),</FONT> filed with the SEC on March&nbsp;7, 2023).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1829802/000095017025046338/snse-ex3_4.htm">Certificate of Elimination of the Series A Junior Participating Cumulative Preferred Stock of the Registrant (incorporated by reference to Exhibit
 3.4 to the Registrant&#8217;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39980),</FONT> filed with the SEC on March&nbsp;28, 2025).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1829802/000119312526056135/d112826dex31.htm">Certificate of Designation of Series <FONT STYLE="white-space:nowrap">B&nbsp;Non-Voting&nbsp;
Convertible</FONT> Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant</A>&#8217;<A HREF="http://www.sec.gov/Archives/edgar/data/1829802/000119312526056135/d112826dex31.htm">s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39980),</FONT> filed with the SEC on February&nbsp;18, 2026).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1829802/000119312526132014/snse-ex4_1.htm">Description of Securities (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> (File No.<U></U><FONT STYLE="white-space:nowrap">&nbsp;001-39980),</FONT> filed with the SEC on March<U></U>&nbsp;30, 2026).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.2&#135;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1829802/000119312526132014/snse-ex4_2.htm">Warrant to Purchase Stock, dated as of September<U></U>&nbsp;
7, 2021, by and between Faeth Therapeutics, Inc. and Western Alliance Bank (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> (File No.<U></U><FONT
STYLE="white-space:nowrap">&nbsp;001-39980),</FONT> filed with the SEC on March<U></U>&nbsp;30, 2026).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d133316dex51.htm">Opinion of Cooley LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1&#135;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1829802/000119312526056135/d112826dex101.htm">Form of Securities Purchase Agreement, dated as of February&nbsp;
17, 2026, by and among Sensei Biotherapeutics, Inc. and each investor listed on Exhibit A thereto (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-39980),</FONT> filed with the SEC on February&nbsp;18, 2026).</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1829802/000119312526056135/d112826dex102.htm">Form of Registration Rights Agreement, by and among Sensei Biotherapeutics, Inc. and certain investors signatory thereto (incorporated by reference
 to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39980),</FONT> filed with the SEC on February&nbsp;18, 2026).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d133316dex231.htm">Consent of Deloitte&nbsp;&amp; Touche LLP, independent registered public accounting firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d133316dex232.htm">Consent of Deloitte&nbsp;&amp; Touche LLP, independent registered public accounting firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney (included on signature page). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d133316dexfilingfees.htm">Filing Fee Table </A></TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#135;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain schedules, annexes and attachments have been omitted pursuant to Item 601(a)(5) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> The registrant agrees to provide, on a supplemental basis, a copy of any omitted schedules, annexes and attachments to the SEC or its staff upon request. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Undertakings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The undersigned Registrant hereby undertakes: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) to include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20&nbsp;percent change in the maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221; in the effective registration
statement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) to include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the registration statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>provided, however</I>, that
subparagraphs (i),(ii), and (iii)&nbsp;do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section&nbsp;13
or Section&nbsp;15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a
new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act to any purchaser: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be
part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on
Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act shall be deemed to be part of and included in the registration
statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes
of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a
document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or
modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) That, for purposes of determining any liability under the Securities Act, each filing of the Registrant&#8217;s annual report pursuant to
Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&nbsp;15(d) of the Exchange Act) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling
persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of
any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of
the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Rockville, Maryland, on April&nbsp;28, 2026.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SENSEI BIOTHERAPEUTICS, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Christopher W. Gerry</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher W. Gerry</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and General Counsel</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>KNOW ALL PERSONS BY THESE PRESENTS</B>, that each person whose signature appears below hereby constitutes and appoints Christopher W. Gerry
and Josiah Craver, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> proxies and agents, each with full power of substitution and resubstitution, for him or her in his or
her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule
462(b) increasing the number of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC and generally to do all such things in his or her name and behalf
in his or her capacity as officers and directors to enable the Company to comply with the provisions of the Securities Act and all requirements of the SEC, granting unto said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> proxies and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in
connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT>
proxies and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to
the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Christopher W. Gerry</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Christopher W. Gerry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">President, General Counsel and Director (<I>Principal Executive
Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">April&nbsp;28, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Josiah Craver</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Josiah Craver</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Senior Vice President of Finance</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Principal Financial Officer and Principal Accounting Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">April&nbsp;28, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Bob Holmen</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Bob Holmen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">April&nbsp;28, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Thomas Ricks</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Thomas Ricks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">April&nbsp;28, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Kristian Humer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kristian Humer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">April&nbsp;28, 2026</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Phillip Donenberg</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phillip Donenberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">April&nbsp;28, 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Anand Parikh</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Anand Parikh</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">April&nbsp;28, 2026</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d133316dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g133316g0426235705486.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madison A. Jones </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 202 728
7087 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">madison.jones@cooley.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;28, 2026 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sensei Biotherapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1405 Research Boulevard, Suite 125
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rockville, MD 20850 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Sensei Biotherapeutics, Inc., a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), in connection with the filing of a
Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the &#8220;<B><I>Registration Statement</I></B>&#8221;) with the Securities and Exchange Commission (the &#8220;<B><I>Commission</I></B>&#8221;) under the Securities Act of
1933, as amended (the &#8220;<B><I>Securities Act</I></B>&#8221;), including a related prospectus included in the Registration Statement (the &#8220;<B><I>Prospectus</I></B>&#8221;), covering the registration for resale of up to 24,868,028 shares
(the &#8220;<B><I>Shares</I></B>&#8221;)<B><I> </I></B>of the Company&#8217;s common stock, par value $0.0001 per share (&#8220;<B><I>Common Stock</I></B>&#8221;) consisting of (i) 10,425,531 shares of Common Stock (&#8220;<B><I>Merger
Shares</I></B>&#8221;) issuable upon the conversion of 10,425.531 shares (&#8220;<B><I>Merger Preferred Shares</I></B>&#8221;) of the Company&#8217;s Series B <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock, par value
$0.0001 per share (&#8220;<B><I>Series B Preferred Stock</I></B>&#8221;), (ii) 14,440,395 shares of Common Stock (the &#8220;<B><I>PIPE Shares</I></B>&#8221;) issuable upon the conversion of 14,440.395 shares of Series B Preferred Stock (the
&#8220;<B><I>PIPE Preferred Shares</I></B>&#8221;) and (iii) 2,102 shares of Common Stock (the &#8220;<B><I>Warrant Shares</I></B>&#8221;) issuable upon exercise of a warrant (the &#8220;<B><I>Warrant</I></B>&#8221;) to purchase 2.1020 shares of
Series B Preferred Stock (the &#8220;<B><I>Warrant Preferred Shares</I></B>&#8221; and, together with the Merger Preferred Shares and the PIPE Preferred Shares, the &#8220;<B><I>Preferred Shares</I></B>&#8221;), which will be exercisable for shares
of Common Stock upon conversion of the Series B Preferred Stock. The Merger Preferred Shares were issued by the Company pursuant to that certain Agreement and Plan of Merger (the &#8220;<B><I>Merger Agreement</I></B>&#8221;), dated February&nbsp;17,
2026, by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company, Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company,
Faeth Holdings Therapeutics, Inc. (&#8220;<B><I>Faeth HoldCo</I></B>&#8221;) and Faeth Therapeutics, LLC, a wholly owned subsidiary of Faeth HoldCo. The PIPE Preferred Shares were issued by the Company pursuant to that certain Securities Purchase
Agreement, dated February&nbsp;17, 2026, by and among the Company and the purchasers named therein (the &#8220;<B><I>Purchase Agreement</I></B>&#8221;). The Warrant was assumed by the Company pursuant to the Merger Agreement and became a warrant to
purchase Series B Preferred Stock in accordance with the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined and relied upon the
Registration Statement, the Prospectus, the Company&#8217;s certificate of incorporation and bylaws, each as currently in effect, the Merger Agreement, the Purchase Agreement and such other records, documents, opinions, certificates, memoranda and
instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to
originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company. We have
also assumed that (i)&nbsp;the requisite stockholder approval of an amendment to the Amended and Restated Certificate of Incorporation (the &#8220;<B><I>Amendment</I></B>&#8221;) to increase the total number of authorized shares of Common Stock to
the extent required to satisfy the Company&#8217;s obligations for the issuance of the Shares upon conversion of the Preferred Shares has been obtained at the Company&#8217;s annual meeting of stockholders to be held on or around June&nbsp;10, 2026
(the &#8220;<B><I>Stockholder Approval</I></B>&#8221;) and (ii)&nbsp;following the Stockholder Approval, the Amendment has been filed with the Secretary of State of the State of Delaware. As to certain factual matters, we have relied upon a
certificate of an officer of the Company and have not independently verified such matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&#8195;1299
Pennsylvania Avenue NW&#8195;Suite 700&#8195;Washington, DC&#8195;20004-2400 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: +1 202 842 7800 f: +1 202 842 7899 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g133316g0426235705486.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;28, 2026 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Two
</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We
express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state anti-fraud law, rule or regulation relating to securities or
to the sale or issuance thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Shares, the Preferred Shares and the Warrant, after giving effect to the assumption as to the
Amendment and the Stockholder Approval stated above, we express no opinion to the extent that future issuances of securities of the Company, antidilution adjustments to outstanding securities of the Company or other matters cause the Series B
Preferred Stock to be convertible into, or the Warrant to be exercisable for, more shares of Common Stock than the number available for issuance by the Company or that the consideration paid upon exercise of the Warrant is below the par value per
share of Series B Preferred Stock. Please note that the shares of Series B Preferred Stock are not convertible into shares of Common Stock until the Company has received the Stockholder Approval and the Amendment has been filed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, in reliance thereon and subject to the assumptions, exceptions, limitations and qualifications set forth herein, we are of the
opinion that (a)&nbsp;the Merger Shares and the PIPE Shares, when issued upon conversion of the Series B Preferred Stock in accordance with the terms of the Series B Preferred Stock, and (b)&nbsp;the Warrant Shares, when issued and paid for in
accordance with the terms of the Warrant and converted in accordance with the terms of the Series B Preferred Stock, will be validly issued, fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters
expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this letter to reflect any facts or circumstances that may hereafter come
to our attention or any changes in law that may hereafter occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the reference to our firm under the caption &#8220;Legal
Matters&#8221; in the Prospectus and to the filing of this opinion as an exhibit to the Registration Statement. In giving such consents, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of
the Securities Act or the rules and regulations of the Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Cooley LLP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Madison A. Jones</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Madison A. Jones</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&#8195;1299
Pennsylvania Avenue NW&#8195;Suite 700&#8195;Washington, DC&#8195;20004-2400 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: +1 202 842 7800 f: +1 202 842 7899 cooley.com </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d133316dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 23.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> of our report dated
March&nbsp;30, 2026 relating to the financial statements of Sensei Biotherapeutics, Inc. appearing in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Sensei Biotherapeutics, Inc. for the year ended December&nbsp;31, 2025.
We also consent to the reference to us under the heading &#8220;Experts&#8221; in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Baltimore, Maryland </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;28, 2026 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>d133316dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 23.2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> of our report dated
April&nbsp;15, 2026, relating to the financial statements of Faeth Therapeutics, Inc., appearing in the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of Sensei Biotherapeutics, Inc. filed on April&nbsp;15, 2026. We also consent
to the reference to us under the heading &#8220;Experts&#8221; in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Baltimore, Maryland </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;28, 2026 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>d133316dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:ffd="http://xbrl.sec.gov/ffd/2026">
<head>
<title>EX-FILING FEES</title>
</head>
  <body>
  <div style="display: none"> <ix:header> <ix:hidden> <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-331">S-3</ix:nonNumeric> <ix:nonNumeric name="ffd:SubmissnTp" contextRef="rc" id="ixv-332">S-3</ix:nonNumeric> <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="rc" id="ixv-333">EX-FILING FEES</ix:nonNumeric> <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="rc" id="ixv-334">0001829802</ix:nonNumeric> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-335">Sensei Biotherapeutics, Inc.</ix:nonNumeric> <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"></ix:nonNumeric> <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ix:nonNumeric> <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd" xlink:type="simple"/> </ix:references> <ix:resources> <xbrli:context id="rc"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001829802</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-04-27</xbrli:startDate> <xbrli:endDate>2026-04-27</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_1"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001829802</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>1</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-04-27</xbrli:startDate> <xbrli:endDate>2026-04-27</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:unit id="USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit> <xbrli:unit id="pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit> <xbrli:unit id="Shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit> </ix:resources> </ix:header> </div> <div>
<table style="width: 99%; font-family: Arial, Helvetica, sans-serif; font-size: 20pt; text-align: center;">
<tr>
<td colspan="4" style="padding-bottom: .5em"> <p> <b>Calculation of Filing Fee Tables</b> </p> </td> </tr>
<tr>
<td style="padding-bottom: .25em"> <p> <b> <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-363">S-3</ix:nonNumeric> </b> </p> </td> </tr>
<tr>
<td style="padding-bottom: .25em"> <p> <b> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-364">Sensei Biotherapeutics, Inc.</ix:nonNumeric> </b> </p> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 1: Newly Registered and Carry Forward Securities</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcOfferingTableNa">&#9744;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; float: center; width: 100%; text-align: center; border: 1px solid black; font-size: 16px;">
<tr style="background-color:#9ADAF6">
<th style="width: 12%;">
 </th>
<th style="width: 2%;">
 </th>
<th style="width: 12%;"> <p style="margin: 0pt; text-align: center;"> <b>Security Type</b> </p> </th>
<th style="width: 14%;"> <p style="margin: 0pt; text-align: center;"> <b>Security Class Title </b> </p> </th>
<th style="width: 2%;"> <p style="margin: 0pt; text-align: center;"> <b>Fee Calculation or Carry Forward Rule</b> </p> </th>
<th style="width: 5%;"> <p style="margin: 0pt; text-align: center;"> <b>Amount Registered</b> </p> </th>
<th style="width: 15%;"> <p style="margin: 0pt; text-align: center;"> <b>Proposed Maximum Offering Price Per Unit</b> </p> </th>
<th style="width: 10%;"> <p style="margin: 0pt; text-align: center;"> <b>Maximum Aggregate Offering Price</b> </p> </th>
<th style="width: 5%;"> <p style="margin: 0pt; text-align: center;"> <b>Fee Rate</b> </p> </th>
<th style="width: 6%;"> <p style="margin: 0pt; text-align: center;"> <b>Amount of Registration Fee</b> </p> </th>
<th style="width: 1%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward Form Type</b> </p> </th>
<th style="width: 7%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward File Number</b> </p> </th>
<th style="width: 6%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward Initial Effective Date</b> </p> </th>
<th style="width: 7%;"> <p style="margin: 0pt; text-align: center;"> <b>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</b> </p> </th> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Newly Registered Securities</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_1" format="ixt:booleanfalse" id="ixv-365">Fees to be Paid</ix:nonNumeric> </td>
<td style="text-align: center;"> 1 </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_1" id="ixv-366">Equity</ix:nonNumeric> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_1" id="ixv-367">Common Stok, par value $0.0001 per share</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule457aFlg" contextRef="offrl_1" format="ixt:booleantrue" id="ixv-368">457(a)</ix:nonNumeric> </td>
<td style="text-align: right;"> <ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="Shares" decimals="0" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-369">24,868,028</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxOfferingPricPerScty" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-370">31.18</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-371">775,385,113.04</ix:nonFraction> </td>
<td style="text-align: right;"> <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="7" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-372">0.0001381</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-373">107,080.68</ix:nonFraction> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fees Previously Paid </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Carry Forward Securities</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Carry Forward Securities </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right">Total Offering Amounts:</p> </td>
<td>
 </td>
<td style="vertical-align: top; width: 16%;"> <p id="MaxAggtOfferingPrice" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-374">775,385,113.04</ix:nonFraction> </p> </td>
<td>
 </td>
<td style="vertical-align: top; border-bottom: 1px black; width: 16%;"> <p id="TotalFeeAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlFeeAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-375">107,080.68</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Total Fees Previously Paid: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="TotalPreviouslyPaidAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-376">0.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Total Fee Offsets: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="TotalOffsetAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-377">0.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Net Fee Due: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="NetFeeAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:NetFeeAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-378">107,080.68</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr> </table> </div> <div>
<table style="width: 100%; text-indent: 0px;"> <tbody>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td> <p style="margin:0pt;text-align:left; margin-bottom: 5px;"> <b>Offering Note</b> </p> </td>
<td/> </tr> </tbody> </table> </div> <div style="padding-bottom: 20px;">
<table style="width: 100%; text-indent: 0px;">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td style="width:10pt;"> <p style="margin:0pt;text-align:left;"> <sup style="vertical-align:top;line-height:120%;font-size:10px">1</sup> </p> </td>
<td colspan="7" style="white-space: pre-line;"> <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_1" id="ixv-379">Consists of an aggregate of up to 24,868,028 shares of the Registrant's common stock, par value $0.0001 per share (the "Common Stock) consisting of (i) 10,425,531 shares of Common Stock, issuable upon the conversion of 10,425.531 shares of the Registrant's Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share ("Series B Preferred Stock"), (ii) 14,440,395 shares of Common Stock issuable upon the conversion of 14,440.395 shares of Series B Preferred Stock and (iii) 2,102 shares of Common Stock issuable upon exercise of a warrant to purchase 2.1020 shares of Series B Preferred Stock, which will be exercisable for shares of Common Stock upon conversion of the Series B Preferred Stock. Pursuant to Rule 416 under the Securities Act of 1933, as amended, the shares of Common Stock being registered hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock being registered hereunder as a result of stock splits, stock dividends or similar transactions. Pursuant to Rule 457(c) under the Securities Act, calculated on the basis of the average of the high and low prices per share of Common Stock reported on The Nasdaq Stock Market on April 21, 2026.</ix:nonNumeric> </td> </tr>
<tr>
<td colspan="7"> <hr style="width:100%;text-align:left;margin-left:0"/> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 2: Fee Offset Claims and Sources</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcOffsetTableNa">&#9745;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; text-align: center; border: 1px solid black;">
<tr style="background-color:#9ADAF6">
<th style="width: 10%; text-align: left;">
 </th>
<th style="width: 8%; text-align: left;">
 </th>
<th style="width: 16%;"> Registrant or Filer Name </th>
<th style="width: 6%;"> Form or Filing Type </th>
<th style="width: 7%;"> File Number </th>
<th style="width: 6%;"> Initial Filing Date </th>
<th style="width: 6%;"> Filing Date </th>
<th style="width: 6%;"> Fee Offset Claimed </th>
<th style="width: 6%;"> Security Type Associated with Fee Offset Claimed </th>
<th style="width: 8%;"> Security Title Associated with Fee Offset Claimed </th>
<th style="width: 6%;"> Unsold Securities Associated with Fee Offset Claimed </th>
<th style="width: 9%;"> Unsold Aggregate Offering Amount Associated with Fee Offset Claimed </th>
<th style="width: 6%;"> Fee Paid with Fee Offset Source </th> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Rules 457(b) and 0-11(a)(2)</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Claims </td>
<td> </td>
<td style="text-align: left;"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Sources </td>
<td> </td>
<td style="text-align: left;"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Rule 457(p)</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Claims </td>
<td> </td>
<td style="text-align: left;"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Sources </td>
<td> </td>
<td style="text-align: left;"> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 3: Combined Prospectuses</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcCombinedProspectusTableNa">&#9745;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; border: 1px solid black;">
<tr style="background-color:#9ADAF6">
<th style="width: 4%">
 </th>
<th style="width: 14%"> <p style="margin: 0pt; text-align: center;"> <b>Security Type</b> </p> </th>
<th style="width: 25%"> <p style="margin: 0pt; text-align: center;"> <b>Security Class Title</b> </p> </th>
<th style="width: 14%"> <p style="margin: 0pt; text-align: center;"> <b>Amount of Securities Previously Registered</b> </p> </th>
<th style="width: 18%"> <p style="margin: 0pt; text-align: center;"> <b>Maximum Aggregate Offering Price of Securities Previously Registered</b> </p> </th>
<th style="width: 6%"> <p style="margin: 0pt; text-align: center;"> <b>Form Type</b> </p> </th>
<th style="width: 10%"> <p style="margin: 0pt; text-align: center;"> <b>File Number</b> </p> </th>
<th style="width: 8%"> <p style="margin: 0pt; text-align: center;"> <b>Initial Effective Date</b> </p> </th> </tr>
<tr style="background-color:#E7E7E2;">
<td style="text-align: center;"> </td>
<td> </td>
<td> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td> </tr> </table> </div> </body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g133316g03g03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g133316g03g03.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1?>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %\$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^$_@FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M&O,&O;I1D^34T6<>+7 H0F2B(HR8SZ1U^=8-DUZEB>6S5+6TL>.!R\X/LRH
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M%>-/VVY0',573QSM/@YH/[UZ2Q?T:+F;EL9T\YQR^G;)3._0D<!_IW5E!1E
MH7],OX2J#_+V?7>IH*%_3+^$JA_R]GUWJPDL"!$0(CV-%_AA8OE\'[1JV9CD
MM9FB_P ,+%\O@_:-6S,<D6!$111$1 1$04<,@@\BHG;5[=);]>7*-N0V603
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M+1\N%R8/I3:L^X?:*1KRYLY!(.1D<0%R>,/^][V\1G/9S7PJG-D<'Q^6&<"
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M;+O=]2T%%IWKVW*65O5/A<6EAS[[(Y8YY6Q_3]-5T=EH::Y5CJVLBB:R:H<
M#(\#B<#O*L;8WLLM>SNTLW&MJ+S,S^DU9'')YM;W-^E9)46!$1%6)MU^"/5/
MR0_6"UW+8CMU^"/5/R0_6"UW]A5A)$"($1.+HB? _%\NG^D+-*PMT1/@?A^7
M3_2%FE1E B(@(B("(B"!O2G^&V_?F4W[!BQ*%EKI3_#;?O\ #IOV#%B95B+*
MW1>^&.T?FR?56*%E?HO?#':/S)/JH)ZHB*,G2O-P@M5JJZ^K>&04T3I7D]P&
M5KDVAZEGU=K&Z7FH<3[IF)C!_%8.#1ZL*5W2^U<;+HBGLE+*!57>0AX!P1"S
MBX^DEH]:A<K"2YQ3RQ<8I'LXY\EQ"R#I7;/KO3;61TE^GJ*9@P(*W[^T#N!=
MQ'H(6.AR50B)-6#I5US&M9?M/0RD<Y*24MS^B[/TK(-EZ2^B*UK?=[ZRW./,
M2P.DQ^H"H1A516P*GVW[/9]TMU)3-R<>6U[?I'!?2?;1L_AP7:GHG9_()=]
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MJB6^Q79]3[/]&04!:QURF^^ULP'OY.X?W0. _P#E7^!@8"HSEP55%$1$!$1
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M*K%L?;S55Q:5R49"(B B(@(B("(B J8SV*J(& A 1$#"8"(@#@B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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C;RJ*L]:_/>,\!Z LAL :    .& B(KFB(@(B("(B B(@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g133316g0426235705486.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g133316g0426235705486.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  M (D# 2(  A$! Q$!_\0
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MZ_)\1?!D$DESE9M0M;8?O4D7&)TQR>@)QW&?6J_PQ_;\_LW38].\=Z1<2WT
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&NX^$/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g133316g08g08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g133316g08g08.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1>D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %X<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUEXC+=UG<3R /66[K.XC+=UG<3R )RW=9W$G+=UEXGD >LMW6=Q&6[K+Q/(
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MK+Q&6[K.XGD >LM_6=Q&6[K+Q/( ]9;NLO$9;^LO$\$@>LMW67B,MW6=Q/(
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M7B>$) ](]W6=Q!Y                       0
M                                              $       %E71Q
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MI? :;:+=@&Z](E1^:P1TB5'5FD$TF]]-M&HE -U3E$J/S6".D.H_-8)I0]"
M;KTAU+YI!'2'4?FD$TKT#T ;KTB5+YK!/4#E"J$2/#ANEH*(YR)H7>:1Z"M)
M_P"LE_ZC?O [\W2B+O1%^PDAO@M_E3[B2*( @
M                  !             (
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M @;+A%1;V4"01_EQV[  "+?_ #4+H!((WZ_.$5-]^U )("+=+Z5  $D
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M;X+?Y4^XDAO@M_E3[B2*           @                    H  @
M  &P                                                   4  0
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MM:=AVZOUJ7HDBZ/'6[[+S<-JZ7KL.-52?B5*H1IN.C4?$72C=2)L](A%H
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M>42M)?ZV7_J-^\#OS?!;_*GW$D)X+?Y4^XDB@
M                              -@
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M>_;D>#V-TZ#!_=N"?XH&2J%:G:C)RLI-/AN@2WP2(VRIHMI4QNPG98 0"0!
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M)6DO];+_ -1OW@=^;X+?Y4^XDAO@-_E3[B2*
M   $  !  ()                0
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MSP3VE26H55;-0'.ITRB(]%551+:_.!VQJ]ZW^5/N)(;?);?7DI?@211
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MVL_K69_F_ LMI\LSOYZ_Z]1@_9'\  <.&P !0          #8-@ !   0 (
M  !-0  !-80(           !   &P     34   0(
M   -@V  $  !  @   $U   $UA @           $   ;     #8!<1T&3IT]
M9$A1E54U(NXRJ?9LMM-870F@R--GK6A1G+;8IZOX;YF:+8.-/3RZW-935]=#
M+Z0A"?XH3:>TIJBJ+PZB8GK$I)()0R0        ()!     %   $
M 0     ( D            !<2DQD+DOOD[]QD6JBI=%OVF%+J5CY"Y+]+5U
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MA.R7PW:VKN*%C9>4I+8]KZ)LF5^Y#6D,)AQJXBFJP@0 C     @"2"0 ()
M;     ;     #8     @D$ 2 @ @D "%/3=:$$LUH!]0<AGR;4O_ '?W*;^[
M4:!R&_)M2_\ =_<IOZ^";*OM=UA]FDUG]:S/\WX%EM+VL_K68_F_ LMI\KSO
M_P!BO^O3X/V1_ ; #B0V " H "P  ( "!        @       &\        (
M$       3:+:  )(0    0   !O ;      #:  "   +   @ ($       "
M $     !O  $D     "       !-HMH  DA       20FK2!O$389*FSRLM#
MC.[W8[<99-GV*FI4-7V*9&G3RMM!BKWJZE4]5\-\S51,8.+/3].MS>5O]=+,
M$D)JNFK82>VB8JB\.HF+  *@ @ (     !                02"  "B"0
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M_K69_F_ LMI\LSO_ -BO^O48/V1_  (<.&P !0   ; /.  "     W@ -X
M   -@ (        !L  (       -@   #S      !       (  &P    V >
M<  $    !O        V  @ 0       ;  "       #8    \P    -81-"J
MH!+Z2[D)-TPMW):$BZ5$C*+'5%==(:+KWF<8U&-R6HB(FI$/1_#_ !%>-5&+
MB1:'!S6:BB--/<AM1B(C;VLB(>SR>CWE-,4Q:'27N  R00    A (0D%  (
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MX .O[-Y!.\("!  %CH @D( @!0$@!8 @ 2  " @"0!L  @GL $$@"$ ) @D
M  $  ( ();K0*2W6@1]0<AGR;4O_ '?W*;^[P30.0SY-Z7_N_N4W]?!-E7VN
MZP^S2:S^M9G^;\"R76I>UG]:S/\ -^!9;5/E>=_/7_7J,'[(_@ $.)#8  H
M       (   "            "    @ ;0     !       2A 0  -X
M                "    @            @   ( &T      0      $H0$
M  $L!>4^468=E.6T-/M$C*+,.RG:(2;=YFV-1C4:U+(FA$W'I/A_B*L>8Q<2
M.C@9K-1AQII[D-J,;9B9*)J0]#S ]UAX<8=,4TNFFJ9F\F\D V,0 $  %
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M6A[5 !J=9:0! "T@ %BT@ %BT@" 6+2  6-,@ L+%I  .J]0 "Q:0 ;!9+2
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MC#IBFG].EJF9ZR(2 ;&(" !(   @D    ( $IM!  D(0 )!!(  @"0" )!
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M1F#>LI> "SS%O64)(MZREX"BSS%+:7+P"2+;Z7*7F@(0>(;$8U&HFA#V0A(
M     (VD@"G'A<ZS)5;%MF*=92]UD 6>8IUE"2*=92\"?YI L\Q3K.&8IUE+
MS_-8_P U@6>8IUG#,4ZREX@O_EP+/,4ZSAF*=92\_P U@HL\Q3K*,Q3K.+S_
M #6/\U@6>8IUE&8IUE+P)_FDA99YBG649BG67@7G^:Q_FL"SS%.LX9BG64O/
M\UC_ #6"RSS%.LHS%.LXO/\ -8_S6!9YBG649BG6<7G^:P!9YBG64E)%$<BY
M2EW_ )K%R@B6)(0D@     !\U>ZM^,5$^CN^\^E3YJ]U;\8J)]'=]YE2.' ;
M ;$0         2!           'UG[FOY,H7TV-]S3Y,/K/W-?R8POIL;[FF
M%0ZDJV0XQRC\J%9P[BN:IDE!EWP(2(J*]%N=H=X*GRWRW_*)/_RM_$USTAIQ
MZIIIZ,KTV8B6]Y>4OV(HZ;,1?-Y3@IRX(8:G X]3J/3;B+YO*6\RA.6S$7S>
M4X*<N%QJ./4ZCTV8B^;RO!1TV8B^;RG!3EP&HX]3J/39B+YO*<%'39B+YO*<
M%.7$#4<>IU+ILQ%\WE."CIMQ%\WE."G+B!J./4ZETVXB^;RG!1TV8B^;RG!3
MEP&HX]3J/39B+YO*<%'39B+YO*<%.7"XU''J=1Z;,1>(E."CILQ%\WE."G+@
M-4G'J=1Z;,1?-Y3@HZ;,1?-Y7@IRX#4<>IU'ILQ%\WE>"CILQ%\WE."G+@-1
MQZG4>FW$7S>4X*.FW$7S>4X*<N%QJ./4ZCTV8BM_IY3@HZ;,0_-Y3@IRX#4<
M>IU'ILQ%\WE."CILQ%\WE."G+@-1QZG4>FS$7S>4X*.FS$7S>4X*<N(&HX]3
MJ739B+YO*<%'39B+YO*<%.7 :CCU.H]-F(OF\IP4=-F(OF\IP4Y<0-1QZG4N
MFS$7S>4X*.FS$7S>4X*<N U''J=1Z;<1?-Y3@HZ;<1?-Y3@IRX#4<>IU'ILQ
M%\WE>"A>6S$7S>4X*<N U''J=1Z;,1?-Y3@I'37B+YO*<%.7@:CCU.HIRV8B
M\1*<%'39B+YO*<%.7 :CCU.H]-N(O$2G!1TV8B\1*<%.7 :I./4ZCTV8B^;R
MG!0G+9B*Z?\ #RG!3EQ*>$@U2<>I];<FU=F,2X1DJI/0VLF(R+E-9JT*IM#K
MF@<AOR<4K_=_<IOYG5,VF7:8?6&,FZU EIA\%S'*YBV544H^^&6ZD0P=:_6D
MQ_-^!9'A<U\[F*,6JBG].[PLGAU41,MI]\,MXN(/?#+>+B&K(+G&Y_FO+9L<
M)M*8AENH\>^&7ZD0U8#G^:\FRPFT^^&6ZD0>^&7\7$-6 Y_FO)L<)M*8BE_%
MQ![X9;Q<0U;T@<_S7E-CAMI]\,MXN(/?#+>+B&K$W'/\UY78X3:/?#+>+B!,
M0RWBXAJP'/\ ->3983:??#+]2(/?%+^+B&K <_S7DV.$VGWPRWBX@]\,MXN(
M:L!S_->38X3:??#+>+B#WPRWBXAJP'^@S7DV.$VGWQ2_BX@]\,OXMYJP'/\
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M-^34IG5]LNZP^S2JU^M)G^9"S+RM?K28_F0LCY7G?SU_UZ;!_'  #C-H
M    !L&H 20    (                      ;P V!>S6 F@1-NPR-/GLC]
M'&7O=B[C+I:UTU;S5[&1I\]D6A1M+570[<>H^&^9G#F,'&GHZ[-935]='=F.
MW8"&Z=2WOIOO)TV/;4U17%X=/,3'=(('I,T2    0@  H!     !  "   $
M              ()      @                (  *    !"  "@     !
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M2@    (  *          (  *                           ($
M  ( ()*     @  H                     (W]I=R<SD_HXBW386HMHL!F
M4[%),?*3"M3(>NC9<OTTZET$5)&\E"-H%O/_  'I,;M,E/\ P/I,;M*B0 !&
MPU_'M<?AW"=0J<)$6-"9:&BI=%>NA#837,?T-^(L(U*FP%M&B,O#54OWR:4
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MBSD2);0^!\)#3T/T>@#?X&('K6J=2XM-F4=-RR3*S#=,.'H5<A>W0; FA$_
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MQB+JTJEU]":2WGH$AR%<GW/24I$G:M-*L-TSD]ZL2VA7+L:F[:9'#E?C87Y
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M:B]K7ZSF/YBR0^59W\]?]>GP?QPD@D@XK: !"@   'F  !           0
M    #8$        0   -@    NH"P$(2$)1+BXR%-G58O-QENW8NXRZ*BHBI
MJ->E)5TS$R6HJ-_:4S\)B0V(Q%6S4LESW?\ \>QL>K#F*^WZ=-GJ*8JO'=[1
M"2$)/3?UUP "  "@         0!(      "  "@ @      &P        ( !
M!*  $               0  4         " )           !  0     V
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MLTFM?K29_F0LD+VM?K28_F0LD/E6=_/7_7J,'\<)()(0XS8    $ (   V
M -00      #8  ":@@       &P  $     -@  >8*H!-I!-Q<"5MDE:4EGS
M$3);H1-:[$$I+/F(N2G@_M+N0SL"$R!"1C$T;]YWOQ/Q-6:JU5_:X>9S,846
MI[I@0V08?-PTLB:^T]Z3T@/?8.#1@T:*(='75-<WE!)"$FYB      0  02
M ()  (               $U (  !  !0   !           !  !0
M   ( 0""04 02  0               )J 0  "  "@   "           " 1
MY@5($)8K[-U;5*$""Z*ZR:&IK4RD.&V&Q&M2R?>(4-L-N2Q-![(H1M)(V@6\
M_P# >DQIDI_X'TF-VE1(  !  !'VDD+K Y3#J51IW+%B9U,HZU57RL#G&\_S
M20_T;..PG%E8GZS,4VGXEH$:AT5)EL:+/<YSS<M$5&LO^S=5U]G:7D2)4Z!R
MF5VJ0Z%.5&3G)>%#A/EEU*UK46^CL4JXBF:UC*G.HLO0(U,@1WMY^:G8G@L:
MY'6:VVE;HFU-H%)\3$-?QW7*-(59U.IDLV&]T9B7>VZ+WK//KOV%A"JS:]6Z
MA*3^+GTBF4I&2L)(<3(BS$1$[Z(Y;+N-JPK2IF1QIB29BP7)*S#(+($38[)1
M4M<U]M*;AK$-86<PT^N4VH14F8$:6@)%BPG:<IKFK;0N^X%:@UZJ1)'$-(D*
ME*U:H22,?)S[G68YC\FZO5=K45>!BJY.LP])PIZ7QQ%G:Q"BP>=DUB*^'%5S
MVM>VUK(B(Y;:=A=5"BU>KX8KL66I4O3($>)"6!36-R8L2$US5>U[D30KK+HT
MGBMP(]6PO&IN',&Q:7D\U$B+-0DA71D1KLEBZ5<NC7H O,35:+,XO9(5>LS&
M'Z)FK8T"/"NU(T1<GO5>B+J17:.PB;I]9BX-Q)*QZVLW(08$2-*3\)Z.B1F9
M"WAQ$W=I>1IZKRL9KJQ0HU4H$S 8D.3A04BQ9:(B(BHYJVNFAVF^U"QPWAN9
M>W$\6FTU]#I51E'P)>FQ'+IC*GPBM_9\VD#.<DM.C2."*4^/48\[S\K#>UL7
M_P!+O4[U.PW!$T&K<FT>9;A:2IT]3YF1F*=";+O6,G>Q531=B[4T&TW ]
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M:!R&_)O2_P#=_<IO^Q39/:7=8?9I-:_6<Q_,A9(7M:_6DS_,A9(?*LY^>O\
MKT^#^. $["#C-@      #>               $     $"      #>$"   @
M!"4VD6L T%>4EG3,5&MT-VKN)DY9TS%LFA$UJNI#.P83(,/FX=T1-J[3O?B?
MB*LU5%=?VN'F<U&%%H[D&$V"Q&,30FM=Y431?<$![_!PJ<*F*:8[.CJKFN;R
MD$!#:Q2                               @  H    $          !
M                                 (  *     @  H    $      &\
M   @    #W+P71G634FM0$O!=&?9-6U3*0H:0VV:ENW>(;&L8C6IH38>R*6
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ME#G^I"^N.X<_U(7UQR_,^DG'P_+&@R?<*?ZD+ZX[A3_5A?7+R[,^DG'P_+&
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M:1&9*ZBAF+.LXJ+ %_F+.LX9BSK. L 7^8LZSAF+.LX"P!?YBSK.&8LZS@+
M%^DBSK.&8LZS@+ %_F+.LX9BSK. L 7^8LZSAF+.LX"P0%_F+.LX9BSKN(+
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MRW_N'/,EY-GB^&PZ"=!KOOD_Y9?K$^^/=+K]8G/,EY-GB^&PV3<+(:ZF(_\
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MGW\->(%Z"RSY/%KQ&??PUX@7M@66??PUXC/D\6O$"]!99]_#7B,^_AKQ O;
MLL^3Q:\1GW\->(%[8%EGW\->(S[^&O$"]L"RS[^&O$9\GBUX@7H++/OX:\1G
MW\->(%Z+%EGW\->(S[^&O$"]!99]_#7B,^_AKQ O;!$++/OW%XC/D\6O$"]L
M"RSY/%KQ&??PUX@7H++/OX:\1GW\->(%Z"RS[^&O$9]_#7B!>@LL^3Q:\1GW
M\->(%X+%GGW\->(S[^&O$"\L-!9Y]_#^T,G45;*Q43?<"\0D\M6Z:-6P]
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M$@" 2 ("$@ A!( @$C8!"$@ ""4 $ D 0"0!!( $ E  (!($ D 02 ! ) $
MD 02$ $ D 0"0 ()" 0"0! TD@" 2 (!( C@+$@"XE9A82HQVEJ_89%JHJ(J
M+=-BF&+B4F%A.R7>!]P&20$-5')=-*+M)(H   !&T"WG_@$\YC$UF3G_ ('T
MF-VE1(        "  ""0              2U.^3SD$L^$3SH!F&ZB2&ZB2*
M(    'S5[JWXQ43Z.[[SZ5/FKW5OQBHGT=WWF5(X< #8B        2A
M        #ZS]S7\F4+Z;&^YI\F+J/K/W-?R90OIL;[FF%0ZD[P3Y<Y;OE"GO
MY6_B?4;O!/ESEN^4.>_E;^)JJ<?,_:T,$$FMU@!L +   #>0@ $@C:$"0 L
M" %D D! #2 H  ( )"7@!  D@DA J?2  () " ])!(4()( D @"002$0"2 )
M!!(4V $!$DMUH02W6@A8?4'(7\F]*_W?W*;^NU#0.0KY-J5_N_N4W_>;*NTN
MZP^S2:U^M)G^9"R+VM?K29_F0LCY5G?SU_UZ;!^R $D'&;0
M"  $    )M  !        $    BV4.TH-&T >X,1T&(CV+9?O,[)3;9AG[Z:
MT-?/4&(Z$]'0ULY-7:=I\;\E7DZ^O6EQLQEXQH_ZV<%M(S39AJWT/VH7)]#R
MN:HS%$5T3T=%B8=6'-I2" FHY5FM( (  *    (               @
M$      $  !       02    (      @D     (  *    (           (
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M.<C(MKHU^4B6O9=*7V%2<Q%6*C6IRGX2DY.*V05&S<U.O<R&CU_8;DHJJOH
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M%$5TNBQ*)HG3*0 <AK          !!(            $         ( D
M         !!(  $  %     0  4        02            !  0  4
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M?2H@I^G@_P!1G]R'E5NJKOTD-56N:J:T5%0POUNXNJ(JU/H7EWMT3TY.UO\
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MD]-C6J[7*E7YO.:Q.1)J,B6:KK(C4W(B:$)-2UXU-IB.[&@ P<- !(    $
M @D 0202!"DMUH W6@1]0\A?R;TK_=_<IO\ O- Y"T_\MZ5YG?W*;]O-D]I=
MWA]FE5K]:3/\R?<62%[6OUI,_P WX%DFH^59W\]?]>FP?QPG81YR2#C-H$
M ;     !      >D       (        $ $D   2!&H+I":@@!-6D]-:L1R-
M8EU718AC7/<C6)=5U&<D)-)9EW=]$5-/8=E\?\=7FZXMV<?'QZ<&F\ID)-LL
MW*5+Q%UEVB62Q":/2>D/HV5R].7HBBET.)B3B5:I""0<EK
M   -@(  *            $ 2 @     "  "@  ()      "  "@02
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M 0  " 1T2""0 10 L3^@;QL $$I]A!)&-@$$E97N  %Q J@!(Z=A   %B"0
M  !  H02 !!( @D "$)! $DMUH02W6((?4'(7\G%*_W?W*;]M4T'D+3_ ,MZ
M7YG?W*;]L6QLGM+NL/LTJM?K28_F0LDU%[6OUI,?S(61\KSOYZ_Z]/@_9"=A
M !Q6P   ;P  %Q< -@  $$H   #:$  (!Z  !!(    0BD@ $   ;0  M9+@
M2FH-8L1Z-9X2["6-<]^2U+N<NA#-R$HV68CG)>*OV'9?'?'5YRNT=FC'QZ<&
M+SW3(R;9=EWV6(NTNT[-8V]I)]$RF4HRM&BB'0XF+5B3>I 0D'+NU
M   0""0                   (  *                 0  $
M         @D      (  *     ""0                       $  !
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M8  L6$() L6$() +  2XLMD D L  6-)8@D"R:0 "QI+  %@6 !8() -*"0
M6+  66P  60"4 LE@ :19;! )!8#=9!+=8@I_P"OJ'D,6W)O2_\ =_<IOW[)
MH/(8G_EO2O\ =_<IOKET=EC95/TNYP^S2ZS^LYG^9"R+RLHBU29T_MI]Q9)H
MU'RO.Q_YZ_Z]/@=<.$@92A%.+9M -(NNX!<#3N%^P !=0BBP7%R-)**NX!<"
MXNNX +BZ[AI 7&T"^O0 N-XOV$746$@747%@%Q?L%_, %P  %^P74!<7 3>
M/4-KGN1K6JKEU(&-<YUF)=3.2,FV72[M,1=:[CLOCOCJ\Y7:.SCX^/3A4_\
M42$HDNW*=IB.^PO+[!;0#Z)E,I1EJ(IIAT6+BSB57D3620A)RVH()&\ $()(
M  * ( $@"X $$@!L   @D    ! $@$ 2" !(! $@#8       " )(  D (0
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M_P#43V#H PGXR?\ 6)[#KP+JD<AZ ,)^,G_6)[!T 83\9/\ K$]AUX#4.0]
M.$_&3_K$]A'0#A/QD_ZQ/8=? U#D'0!A/QD_ZQ/83T 83\9/^L3V'7@-0Y!T
M X3\9/\ K$]@Z ,)V^$G_6)[#KX&H<@Z ,)^-G_6)[!T 83\;/\ K$]AU\#4
M.0= &$_&S_K$]@Z ,)^,G_6)[#KX&H<@Z <)^,G_ %B>P= &$_&3_K$]AU\#
M4.0= .$_&3_K$]A/0#A/QD_ZQ/8=> U#D'0!A-47])/^L3V'0,%87D,(4)M*
MI7.K+-BNBHZ(Z[E5UK_<9\A"7N(31=#GF+.2NF8EK<>IS<[-0XT5$160U2R<
M4.B;1HTZ"68U4Q5%I<B3D,HB)^L)[ZR>PGH-HGE&>^LWV'7-&ZY&@EF'"I<D
MZ#*)Y1GOK-]@Z#:)Y0G_ *R?]IUQ/0!8X5+D:<AM$M^L)[ZS?^T=!E%\HSWU
MF_\ :=<MO%O\N+'!I<CZ#*)Y1GOK-_[1T&T7RC/?6;_VG7/0+%M!P:7(^@RB
M>4)[ZR>P=!E$\H3WUD]AULD6.#2Y'T&T7RC/<6_]HZ#*)Y1G_K-_[3KFP)YQ
M8X-+D?091/*,]]9/^T=!E$\H3WUD]AUP:!:#@TN1]!E%\HS_ -9O_:.@RB>4
M9[ZS?^TZY8"QP:7(N@RB>49[ZR?]I*<AM$\HSWUD_P"TZX+(+0<*ER/H-HGE
M">^LGL'0;1/*$]]9OL.N*0GF%H.#2Y)T&T3RA/?6;[!T&T3RA/?63V'7-%]0
ML+0<&ER/H-HGE&>XI_VCH-HGE&>XI[#K>CL)L+0<&ER/H-HGE&>XI_VCH,HE
MOUA/?63V'7!Z1:#@TN1IR&43RA/?63V#H,HOE">^LW_M.N>E!L%H.#2Y'T&4
M3RA/?63_ +0G(91/*,]]9/8=<3T$"R\&ER3H-HGE">^LWV#H-HGE">^LWV'6
M[$V):$X-+D?0;1/*$]]9O_:.@RB6_6$_]9O_ &G7+!->DMC@TN1]!M$\HSWU
MF_\ :$Y#:)Y1GOK)[#KED""QP:7(^@VB>4)[ZR>P=!M$\H3WUD]AUP7\PL<*
MER+H,HGE&>^LWV$]!M%\H3WUF^PZYP'H%CA4N1]!M$\HSWUD]@Z#*)Y1GOK)
M_P!IUP:!:#@TN1]!M$\HSWUF_P#:.@VB>49[ZR>PZYZ0+0<*ER/H-HGE&>^L
MGL"<AM$3_P#D9[1VI_VG6[H!8C"I8;!U @88H$M2I6(^)!@71'/TJMUN9K1K
M740BW%]!+=+-D=& J%#BS$Y%C-BL1KUNB*A03#L?QT/@;,FK43Z#I<7X/+8M
M4UU=Y<RC.8E,6AJ_O=F/'0^ ][LQXZ&;1;L'H-?^?RK+>XK5TP[,>-ACWNS'
MCH9M&@A!_G\H;[%:Q[W9CQT/@/>[,>.AFSZ"4T[!_G\IX-]BM7][LQXZ'P'O
M=F/'0^!M"V&@?Y_*&]Q6L>]V8\=#X$>]V8\;#X&T)9-@OYR\@RAO<5J_O=C^
M-AA,.S'C89M&@);<3_/Y0WV*U?WNS'C88][LQXV&;1Z!H'^?RG@WV(U?WNS'
MCH8][TQXZ&;1Z!Z!_G\IX-]BM7][LQXZ&/>['\=#^TV?T$[-0_S^4-]BM7][
MLQXU@][LQXV&;/="4MN+_G\IX-]BM7][LQXZ'P'O=F/'0^!M.@@?Y_*^#?8C
M6$P['\=#X$>]V/XZ'P-HMHM<#_/Y7]0F^Q6KIAV/XZ'P'O=C^.9P-HN!_GLK
MX-]B-7][LQIM&A\"?>['M\-#X&SA"_Y[*>#?8K"2-%S=JJKVN?O+O,7==%4R
M/H(.TR^5P\O3IPXLX^)B58DWJE8))/ZZ#,7]9"_0DY+6Q^9/ZR#,7]9#( #'
MYD_KH,R?UD,@ ,?F3^L@S)_60R  Q^9/ZR#,G]9#( #'YD_K(,Q?;PD,@ ,?
MF3^L@S%_60R  Q^8OZR#,G]9#( #'YB_KH,Q?UD,@ ,>DD_K(,R?UT,@ ,?F
M+^L@S)_60R  Q^8OZR#,7]9#( #'YD_K(,R?UD,@ ,?F3^L@S%_60R !9C\R
M?UD&9/ZR&0!1C\Q?UD&9/ZR&0!!C\R?UT&8OZR&0 &/S)_609B_KH9 %&/S%
M_709D_K(9 $&/S)_609D_K(9  8_,7]9!F3^LAD !C\Q?UD&8OZR&00%&/S)
M_609D_K(9 $&/S)_709D_K(9  8_,G]9!F+^LAD !C\R?UT&9/ZR&0 &/S)_
M609B_K(9  8_,G]9!F3^LAD !C\R?UD&9/MX:&0 &/S)_60)(OZR&0 &/S%_
M609D_K(9  8_,7]=!F3^LAD 48]))_609D_K(9 $&/S%_609D_K(9  8_,7]
M9!F+^LAD !C\Q?UD&9/ZR&0 &/S)_609B_K(9  LQ^9/ZR#,G]9#( HQ^9/Z
MR#,G]9#( #'YD_KH,Q?UD,@"#'YD_K(,Q?UD,@"C'YB_KH,R?UD,@"#'YD_K
M(,R?UD,@ ,?F+^L@S)_60R  Q^8OZR#,7]9#(("C'YD_K(,R?UT,@"#'YD_K
MH,R?UD,@"C'YB[KH2V1<CD5SD5NU$+\$'F&U&MLFI-1Z          \18:16
M*UVHH))0^WB71'$"VS*'^]Q&90[?M%SZ!Z +;,H>]>(S*'O<77H'H M<RA?O
M#,H>]>)=#T 6N90]Z\1F4/\ >+KT#T 6N90]ZC,H>]W$NO0/0!:YE#[>(S*'
MV\2YT[B?0!:YE#WJ,RA_O<2Z] ] ++7,H?;Q&90]Z\2ZT[AZ +7,H?[W$9E#
MWKQ+KT$:=P%MF4/>HS*'O7B77H'H M<RA_O<0V3A(M]*VTZRZ]!&K2 ;9$T$
MC>  "    &PU[$V+J3AR8@0:K'BPXD5JN8C(2NT<38+7.*\OWZZI=_$J!N"<
MJ6&$_P#NYG_IE]H3E2PS;_5S/_2K[3Y]V;1J*CZ#Z4L,_.YG_I5]HZ4L,_.Y
MG_I5]I\^W47 ^@NE+#/SN9_Z9?:.E+#/SN9_Z5?:?/OI%^T#Z"Z4L,_.YG_I
M5]HZ4L,_/)G_ *9?:?/MQI ^@DY4L,_.YG_I5]HZ4L,_/)G_ *9?:?/MQ<#Z
M"Z4L,_.YG_I5]HZ4L,_/)G_I5]I\^W'I ^@NE+#/SN9_Z9?:.E+#/SN9_P"E
M7VGS[<>D#Z"Z4L,_.YG_ *5?:1TI89^>3/\ TJ^T^?D\XOV@?072EAGYY,_]
M*OM'2EAGYW,_],OM/GS3O)N!] KRI89LO_%S*^:57VFSX>K4G7Z8V?IKWOEW
M/<R[VY"HJ:]!\K*NA=9] \BB)[Q(?TJ+]R$5O5SF_*#RG,PC6V4]:8Z9RF(]
M8B1$:GW'2%THI\V^Z!M[]85OFS23T:<:J::>C94Y>&>0G^N3V$=/$/R$_P!<
MGL.' PU.%N*G<4Y>(?D%WKD]A/3PSR$_UR>PX:+C4FYJ=RZ>&>0G^N3V#IX9
MY!=ZY/8<- UFYK=RZ>&>0G^N3V#IX9Y"?ZY/8<- U&YK=RZ>(?D)_KD]@Z>&
M>0G^N3V'#0-9N:W<>GAGD)_KD]A/3PSR$[UR>PX:!J-S4[ET[P_(3O7)[!T\
M,\A.]<GL.&H!J-S4[ET\,\A/]<GL'3PR_P"HG^N3V'#0-2[FIW+IX9Y"=ZY/
M8.GB';]1/]<GL.&@:DW-3N73O#\A/]<GL'3PSR$[UR>PX:!J-S6[ET\,\@N]
M<GL'3Q#\A.]<GL.&@:C<U.Y=/$/R"[UR>P=/$/R$[UR>PX:!J-S4[DG+PSR$
M_P!<GL'3PSR$[UR>PX:!J-S4[DG+PSR$[UR>P=.[/(3_ %R>PX:FH<!J-S4[
MCT[L\A/]<GL)3EX9Y"=ZY/8<- U&YJ=R3EX9Y"?ZY/8.GAGD)_KD]APVX&HW
M-3N73O#\A/\ 7)[ G+PSR$_UR>PX:$&HW-3N73PSR$_UR>PCIWA^0G>N3V'#
MB!J-S6[GT\0_(3O7)[!T\0_(3O7)[#AH&HW-;N73NSR$[UR>P=/#/(3O7)[#
MAJ :C<UNY=.\/R$[UR>P=.\/R$_UR>PX82@U&YK=RZ>&>0G>N3V$=/$/R$_U
MR>PX<!J-S4[CT\,\A.]<GL"\O#-E!?ZY/8<."#4L9BI]<\G>*V8OH+ZBV565
MR8RPLA77U)<V55LBKM0YA[GGXCQE3YX[^U#I[O!6^XF+5,43,.QP?JB+M<?B
M&(UZHD%JHBVO<CWQQ;? -^L86+\)$\YX0^>8WS&:BN8BIZ"C*8=NS.^^*+XA
MO$GWQ1?$-XF!!JYQF_9EM,+PSWOBB^(9Q(]\4;Q#.)@T YQF_8VF%X9SWQ1O
M$-XD^^*+XAO$P5R-.X<XS?L;3"\,[[XHOB&\2??%%\0WZQ@KBZCG&;]S:87A
MG??%%\0WB1[XHWB&\3!Z0.<9OW-IA>&<]\4;Q#>(]\4;Q#>)@P.<9OV-IA>&
M=3$47Q#>(]\4;Q#.)@@.<9OV-IA>&<]\4;Q#>)/OBB^(;Q,$+CG&;]C:87AG
M$Q%&\0WB3[XHOB&\3! <XS?L;3"\,[[XHOB&\1[XHOB&\3 Z0.<9OV-IA>&>
M]\<7Q#>)'OCBIK@-XF"0>@<XS7L;3"\-KDJPV:;X",B)X2*OW%TD]^Y]II<)
M7PW935LJ&=D9M)EEET1$UHAZ;XCYJ,?_ ,>+W<#-9/1]5'9E\^_<^T9_^Y]I
M9C:>GB;NN7B3W[J<1GW[J<2S0($7F??NIQ&??N_:6@*+O/EZOVC/OW4XEH +
MO/OW4XC/EZJ<2T %WGR]5.(SY>JG$M !=Y\O53B,^_=^TLR0+O/EZJ<0D^O5
M3B69(%WGW[J<1GR]5.):#8!=Y\O53B,^_=^TM @%WGW[J<1GZ]5.): "[SY>
MJG$9\O53B68 O,^_=3B,^7JIQ+0@@O,^_=^T9]^ZA9D@7>?+U4XC/EZJ<2SL
M2!=Y\O53B,^7JIQ+0%%WGR]5.(SY>JG$M 07:3R]5.(SY>JG$LR2B[SY>JG$
M9\O53B6@ N\^7JIQ&?+U4XEH0!>9^O53B,^7JH6@ N\^7JIQ&?+U4XEF +S/
MEZJ<1GZ]5.)9D@7>?+U4XC/EZJ<2T %VD\O53B,_7JIQ+0@"\SY>JG$9]^ZG
M$M !=Y\O5^T9\O53B6@ N\^7JIQ&?+U4XEH +O/EZJ<1GZ]5.): "[SY>JG$
M9]^[]I9D@7>?+U4XA)_]U.)9@"\S[]U.(SY>JG$M!L N\^7J_:,^_=^TM @%
MWGW[J<1GZ]5.): "[SY>JG$9\O53B68 O,^_=^T9\O53B6A!!>9]^[]HS[]U
M.)9D@7>?+U4XC/EZJ<2T %WGR]5.(SY>JG$M 47>?+U4XC/EZJ<2T %WGR]5
M.(SY>JG$LR0+O/EZJ<1GR]5.): "[SY>JG$9\O53B6A %YGZ]5.(SY>JA: "
M[SY>JG$9\O53B68 O,^7JIQ&?+U4XEF2!=Y\O5^T9\O53B6@ NTGEZJ<1GR]
M5.):$ 7F?+U4XC/OW4XEH +O/EZOVC/OW4XEH +M)Y>K]I[A3B.?9R6N6 ](
M&:33V@L).8R;,?JWE^BWT[%(J0 @   $ (4"E,Q%A0\INLM5G8FY"O/_  'I
M,:U+%1=YZ_<@SV)N0M0!<YZ_<A.>Q-R%H +O/7[D&>OW(6I %WGK]R#/7[D+
M0D"ZSV)N0C/7[D+8 76>OW(,]B;D+4@"[SV)N09[$W(6H NL]B;D&>Q-R%H
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MG!FKLT8&3Q'0JAAR?9)UB D&8?#YUK6OR^]O;7YT,82R5433W""1L^X68Z9
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M99=$1/"/;?#_ #$8T1A8O=U&;RFGZJ%V2AY124VGJ>[KK)!!)(0\P * V
M  !"$D  %       !  !0     !L     ""0
M'F   ;      A"2 ""2@       @  H      V     !!(
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M.TJ3CXSJ\S"FYJUH,HE\E%W^;>8O'V )?#D.C3M-G735,J<5D-BO\)J.THO
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M^$?YSQO/E6-^2K^O4T?;!M4C820:X9         0       !      #>
M $$HNL0GOAO1S5M;403K2QG17-$WI28OT9V1FVQVV=H>FM"[2^W6:Q">L-Z.
M:JI;:9N1FVS#-.B(FM+ZSVWPWS$8L<+%GJZC-Y33.JGLO $)/41-W6V  4
M@ ( 0  4""4             -@(  *   !     ;P  "     V    " @ *!
M!((  *       $ ! "  "@02"  "@        !L       "     W@  $
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M9$DWTU)>*]$NV.CG.1UMZ654,9(<]-1)# ,=SE?3IW.([K^'+MM$A^A'=[Z
M.A0<2P75JG4N+*3$.:G95)ENB[&(J*ME7?H,\E]NLL(E4D(57@TQ\S ;/16+
M$AP%5,MS=.E$UVT+P+Y/0FP"4)  $L^$;YT()9X;?.@&8;X*$D-U$D436
M  (<4Y?OUU2_Z+CM:'%.7[]<TO\ H. Y9^SP)'[/ %  !  !0 !     !)
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M"C?"/\Y3WE2-\(_SE--I\IQOR5/4T?:D@G>0:F0@ *   !!L&P @  ;
M         !    !  0$71;:2QSH3D<U=**1;6IZAL?%>C6I=39A:M<:.Z3:W
M5G)";28;9=#V[%V^8NRUD91LNVZW6(J:5+K8?3OC>-P(XO=YW,:-<Z>R002=
M@T    !        0!(       "     !"$@
M            0       $ 2        @    @$(2"@
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M*QD94[Y&K>Z?:I=IHM:Z$@"$["=@  EGAM\Z$$L\-OG0#,)X*$D-U(210!
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M,?\ '4[G+]H:%%^%?YRFFTJ1?A'^<IIM/E6/^2IZFC[8 3O(-;(
M  !       -( 0  @   "2 2 (3M!ZAL=$<C6I=RF5%$USIA)FT7DAL=$B(Q
MB753.R,HV7AHJV6(J:5$E)MEV7LBQ%37N+KSGMOA_AXP8XN+'5T^:S>OZ:>P
M-@0'J8BSKKW2 @            @        ()    $        " @  H
M              @  H (            (        ""0   !         @(
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M)>(L)UM*+9;:"WU[@JK>ZW5=XNO$Z67]8JLQ5H\*--*W*APFP6Y*6[UJ60L
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MT]C;K )0]1$:>D.N0"00    "%  $ $$E          $ (   !0   !  0
M  @          $  %             0  A0   $$@           " $  %
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M(&-SV-^Z,]B[F\"C) QN>Q=S1GL7L R0,;GL7]T9Y%_= R0,;GL7]T9[%W-
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MNYO #) QN>Q=S1GL7<TJ,D#&YY%7J\"I G%5UHFW<15\"$6Z:R0
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M:CT[6MCR?**_NEZF.P@ ,5 -X     $    $     +;@+B/^#(4Z=YM4AQ?
MV.,PFE#5S(TZ=YMW-15[U=2[CU'PWS,X<Q@XW9UV:RFJ]=/=F/,H(32F@E#V
MU%451>'3S%@D@DS0           @D                 02  0        !
M   0               $$@           ()                 $$@ $
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M[U-\F?\ 3Q/Y%,<S^*K^.YP.\-#=X2^<\GI_A*>4/E-?W2]33V  8*   $
M           $UJ  "(JHM@2W6!?T^>6&Y(<5;MU(NXS#51;JBZ%-7L9"0GEA
MVAQ5NQ="+N/4?#?,SA3P<:>CKLUE(J^NEF23RBWTHN@E#VU%<5Q>'3S$QW2
M#-             0  4         @                  $$D  %     0
M 4                  0  4         @                  $$D  %
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M2$D)J)(H @    AQ3E^_7-+_ *+CM:'%.7[]<TO^BX#EB^#P)(7P>!)42"
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M0D     !!!*  H       (  * ":@     $  @HD    !!( !
MV          "$)      0!*          @  H )J      0 ""B0    $$@
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ML8V:8U6Y+\I.\<U=*+J-PQ+)3DYCO$+9"<65YJFMBQ%M?G&(UMVB*67"^ES
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MF\W?Z*4_>$TW"#4>MCM9U82 4 $         ! $!  !0
M   @D            0   $"$  %       0   0    !00!
M          ""0           !    0(0  4      !   !  !0  ! $   A$
MNNA+@2FO1KW%_*RV0F5$\(2DMD=\]+NW;BZ0"2-I)!%6\_\  ^DQNTR4_P#
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MJ)(;X*$D4     $.*<OWZZI?]!QVM#BG+]^NJ7_0<!RQ?!X$D+JX$E  !
M"2       20  !)    #Z!Y$_B'#^E1?N0^?MA] \B?Q$A_2HOW(!O2GS!RZ
M)_Y@S7]%GXGT^X^8>73Y0)G^DS\3"KLXV9^Q@,!TONK6WL=,QI># @NCQ70%
M5(BL;:Z-[5N9_!%3H<?&]$@4+#K4?G+52)%BN>]NOOK(ZV@TJD5.;H\_"GJ?
M%6',0ENU=BIN5-J&?G,<U&- =#DY61ISGJBOB2L/)>ZW;L0D3T<6FJ(AL$-U
MH'*BB+I685%1-U]1A>3%ZI-UYS76=W+BZ?\ <PQDYBNISCJGSCH3>Z+&0YG(
M8B9:-U+V+O4QU*JDU2G3+I-S6K'A+ B72]VJJ7^Y!<FML/).J^_26_HQ-?F*
MCD_\LH"(FGNM"T<36Z/4YFCU!L[(N1L=K58BN2Z6762M6F^Y3:=EIFK8S9A&
M_OIMN(E::XO#8N6%RNY2*PJJM\F&E^Q&J;!1(C653D[=$<VZPIID-U_!>N6C
M3GM>JLU7*I'J-0<UTU&LCU:EDLFHB=JLW.2LA F'HC)%JM@*W0J(KLK6G:-2
M1B1%4U*=89&@5>=EYM5SIL9S8B7TN==;\39L?HL.4PY+1U_XR#3V\ZU4TM1;
M*U%[4;8IP<>U-D.&L64I\Q-0VHUDS%@HL1+:E7>IK=0G9BH3D:;G(KHLQ%=E
M/>NT3)-6F&;P13H<W,STS-1YB')2<NL6.V76T2(V]LE.)L/)[4Z1-XTIT*A8
M=APD3*58T2(Y[X;<E=/A*B&ET.L3E$GTG*?$1L9$R5:Y+M<U=:*FTS<SCNJ.
M6'W/EY*F9+D>Y96'DK$5-Z[NP7*:HAD9]KH^ Z\DMWRPJMSD=&KI5MD1%\U[
M&L8:DIZIQYGN5&2$L&"Y\6*KK(C;:4OVZK=I<0\55.!B"8K,)T)DU,(C8S$9
M:$]+6LK=17J^,)^HT^+(,EY22E8JHZ*R5AY.6J+=+KZ$%UU0VN@Q8<->358R
MM1%298BKILY7O1OVV.=5]KI:L5&7FT<R,V/%RF.32JJY?O/<U4YF9D:?*1'(
MD*0RN85NA6JJJJK?SJ;"S'U5R(;H\K3YB;AM1K)N-!1T1+:E5=2J+W*L2FI=
M<ILM.RDGA:#45O,-I]UNMU1%>MOL,?R9JK<8R:HMK,BK=-GZ-QA:E59RILEF
MST9T999KFL>YUW65RN6Z^=3S2:C,4J>ASLDY&QV(J-54O:Z67[R,*IB9NRF&
MW7QU3].G/FK_ .\H5N(Y^+9I[G*KEG%6^_OBPE9Z-+5&'/053.(<3G6JJ?M7
MN>(TU%C3SYN(Y%CNB<XJV_:O>XNDU1^G6)"-+,Q#REPYJ36=5\.&Y8".5JO:
MC>^LJ*AKF%JQ08]=D4H>%;U%'HZ%:9=WJHJ:5[[5YS5VUZHMK[ZW#C<W4'Q.
M<<YNI5LB65-J:#,3..ZC%EX\.5E*?)1([59$CRT+)B.1=:7V>@MVZ<6+W7E-
MB(N",:.5J0_TD)58UUT3OEU+N+&FP*73\*0:E763$[!F9AT.7E8<3)AM<U&J
MKGZ4TZ4U;C&X=Q%/4'GVR208L*83)C08S<IC_/Q+JCXNGJ7!F9=)>4F928B+
M&?+QX:.:CUVMW:A=C%4-BI\W+3?)KB2+)4F%(2R/A-2(Q7+SBW71=RKJ,?CF
M%&;A;!<R]7+*=ST8U;Z$=MXEE$QQ67Q(J0UEH4M$A+!S1L-$A-1=J)O[3Q3L
M9523@0)9>8F)&%";!27C0\IJHE[+V+I74+FNFTPOL'JC,%8MCQM,JZ%"AM5?
MVG]_:W;KXD<K#VNQ-"FX29,C,2D)99^IJL2^A/,8K$&))VN08$"89!EY6!=6
M0)=F0Q%7:J;5T%:BXMGZ;3FR+X$M/2;7*YD&99E)#5==EUHG8+FNFUF1IEX/
M)/6'S'P,S4(#)9%U*]'-NJ?9I-NFK>_[%J:T6BV_]K3F5>KL[7(\&).N8V'
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M.^]3?9G_ $\7^129C\57\=[@?IH3O"4\H>G>$IY34?*,3[I>ICL:P@!BH
M     +     3: -@ ($&P 022B*[0B*JKJ+3$U3:$O8:BN5$;I5=2&8I\DD%
M$B1418B[-PI\FD%J1(J=\JIZ#(:KGL?A?AK1QL:'59O-_P#YH A%M))ZZ(BF
M.CJ[];I()   %  $  %          $  %              0  $   $$@
M0            0  4    !  !0         !  !0             $  !
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M9ARN=%:EU545;6<J:NT#H*;T),-@VJ/K6%:74HS<F-,0;Q$35EIH<OI6ZF9
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MY!)Z^(TQ:'5_] 2@ (                 "  "@    0   !!(
M           -X  @D                        $  %     @    !O
M                 -X  @D                     (32ZR:]P$V55LFLO
MY27R$RW^%N$I+HU$>Y.^+H@$H %   (VD@"VG_@/28TR4_\  >DQJ:RHD
M  ()( UO$]#F*I7<-SL")#;"IT9\2*CDTJBM<FCB7&,L/PL2T"+3XCW0(J*D
M2!';X4&(FI6_:GF53.:QN YO3L#5*%@JGR\:?ALKU.G(D] F$;E,<]RK='(B
MWLM]BF0GH&+,1M@2,_!EJ')LB-BQX\K$RXD5&K?)9I[UJVTWN;NB;M@1+:M&
MP#2X]/KM$Q74ZE1)25J,G5,A\6%&=D+!>UN2BHM[*W0FC68Z!A"K1GXMF:A'
MEW35:EVL:UC51L-4R41$NM[(B'1<E%UV)1-8&LU'#"5/!,M0IF/S,:%+P&MC
ML;?(B0VI9R(O:AB9MF-:I2G4>9EJ?*.C0N8CU1CE57-M97-9>Z.7MT:3>U37
MYK!43LN!:46GP:32).G2U^9E8383576ZR655[5UEZ0B:R0 W@    )9X;?.A
M ;X: 9ENI"2&^"A)%$     /,:)RBX'BXLGI68A3L.72!#5F2YBNOVF]D>8#
MC/0W,>6(/JG$IR-S'EB#ZEQV9 !QGH;F/+$+U+AT-S'EB%ZEQV8 <9Z&YCRQ
M"]2HZ')CRQ"]2IV8 <9Z&YCRQ"]2HZ&YCRQ!]2X[, .,IR-S'EB%ZE1T-S'E
MB%ZEQV8 <9Z&YCRQ"]2X=#<QY8A>I4[, .,]#<QY8A>I<.AN9\L0O4J=F '&
M>AN8\L0O4J.AN8\L0O4N.S #C/0W,>6(7J5'0W,>6(7J7'9@!QCH;F+?KB%Z
MEQT; ] ?AG#[::^.V.](SHN6B9*6=;V&PD(E@"Z=1R?'_);,XHQ)&J<*IPY=
MCH;6\VZ$JJBI<ZQ;1H%M**JKHU!C51%46EP1.0J<\MP/4J3T%3?EN#ZEQWE$
MLEKDV[26AJX%/AP7H*F_+<#U+AT%3?EJ#ZEQWJR"PLO H\."]!4YY:@^I<.@
MJ;\MP/4J=ZL+(+' H\."]!4YY;@>I4=!4YY:@>I<=ZL+=JBQP:7!.@N;\M0/
M4N)Z"YSRU ]2X[U;M%A8X%+@O05-^6X'J5'05.>6X/J5.]6%A8X%+@O05.>6
MX/J5'05.>6H/J5.]606%C@4N")R%3GEJ!ZEQ/05.>6X'J5.]6T$6%C@4N"]!
M4YY:@>I4=!4WY;@^I4[U86%C@4^'!N@J<\MP/4N(Z"YORW ]2X[VE]HL+' I
M<%3D*G/+4'U*D=!4YY;@^I4[W86%C@4N"]!4YY:@^I4=!4YY;@>I4[S8FPL<
M"EP7H*G/+4#U+@G(5.>6H'J7'>K"UA8X%#@O05-^6H'J7#H*G/+4#U+CO5E(
ML+' H\.#=!4YY:@>I<.@J;\M0/4N.]"W:+' H<%Z"ISRU ]2XCH+F_+4'U+C
MO=A;M%C@4."]!<WY:@>I<1T%S?EJ!ZEQWM$%A8X%+@G07-^6X'J7$]!,YY;@
M^I4[U86%C@4N"=!4YY:@^I<.@J<\M0/4N.]6)1!8X%+@O05.>6X'J7#H*G/+
M<#U*G>K=HL+'!I<$Z"ISRW ]2X=!4YY;@>I<=ZL+=HL<&EP;H*F_+<#U+B.@
MJ;\MP/4N.]V[19!8X%+@G07-^6X'J7$IR%S?EN!ZAQWJP1+*+0<"GPUOD^PZ
M_"V&9:E19AL=\)558C6V32IL3V+$AO:J:')8]6T6T=JBQ)IBJ+2W4QI[,'[W
M)>_PT7BGL'O<E_'1>*>PSB:$L-.\ZR?ALI,WTN3N\7RP?O<E_'1N*>P>]R!X
MZ+Q3V&<0FY.2Y7U-WB^6"][<OXZ-Q3V#WN0/'1OL]AG?0@0<ERGJ;O%\L#[W
M('CHWV>P>]R!XZ-]GL,\!R7*>IN\7RP7O<@6^&B\4]@][DOXZ-Q3V&= Y+E/
M4W>+Y8+WN0/'1N*>P>]R!XZ-Q3V&=X@<ERGJ;O%\L%[W('CHW%/8/>Y \=&^
MSV&=]"#@.2Y3U-WB^6"][D#QT;[/81[W)?QT7[/89X#DN5]3=XOE@?>Y+^.B
M\4]A6E:'+P'*[+>YVRZF8(0SP_B,MAU1533V2K-8M46F5HDBS:YW$)(LVN<7
M9-CLHBT6AQUGF+.LX9BSK.XEX0B%%JDBQ-KN(229O=Q+I/.2!:9DS>[B,R9O
M=Q+L@"US)F]W$9DS>[B78 M$DF;W<1F3-[N)=CT@6F9,WNXC,F;W<2[0>D"T
MS)F]W$9DS>[B77I %KF3-[N(S)F]W$N_2 +3,F;W<1F3-[N)=^D%%IF3-[N(
MS)F]W$NO2206F9,WNXC,F;W<2[ %IF3-[N(S)F]W$NR +7,F;UXC,F;W<2['
MI M,R9O=Q&9,WNXEV1Z0+7,F;W<1F3-[N)=@"TS)F]W$9DS>[B79 %KF3-[N
M(S)F]W$NP!:9DS>[B,R9O=Q+OT@"TS)N]W$9DS>[B7=@!:9DS>[B,R9O=Q+L
M 6F9,WNXC,F;W<2[( M<R9O=Q&9,WNXEV +3,F;W<1F3-[N)=$@6F9,WNXC,
MF;W<2[])'I M<R9O=Q"23-[N)=>DD"TS)F]W$9DS>[B79 %KF3-[N(S)F]W$
MNP!:)),WNXC,F;W<2['I*+3,F;W<1F3-[N)=H/206F9,WNXA))F]W$NO2 +7
M,F;W<1F3-[N)=^D 6F9,WNXC,F;W<2[](*+3,F;W<1F3-[N)=>DD@M,R9O=Q
M&9,WNXEV +3,F;W<1F3-[N)=D 6N9,WKQ&9,WNXEV +3,F;W<1F3-[N)=D>D
M"US)F]W$9DS>[B78 M,R9O=Q&9,WNXEV0!:YDS>[B,R9O=Q+L 6B23-[N(S)
MF]W$N_2 +3,F[W<1F3-[N)=V %IF3-[N(S)F]W$NP!:9DS>[B,R9O=Q+L@"U
MS)F]W$9DS>[B7?I %IF3-[N(S)F]W$NB0+3,F;W<1F3-[N)=^DCT@6N9,WNX
MA))F]W$NO22!:9DS>[B,R9O=Q+L@"US)F]W$9DS>[B78 M$DF;W<1F3-[N)=
MCT@6F9,WNXC,F;W<2[0>D"SS)F]W$E))F]W$NO2 +3,6;W<2I!E60UOI7SEQ
MZ2 )3>!O         %.-#2*S)5;>8M\RA]9W$O !:9DS>[B,R9O=Q+LCT@6N
M9,WNXC,F;W<2[ %IF3-[N(S)F]W$NR +3,6;W<1F+-[N)> "SS%F]W$9BS>[
MB7@ M,Q9O=Q(S%F]W$O !:9BS>[B1F+-Z\2\ %HDBS>[B,R9O=Q+LCT@6N9,
MWNXC,F;W<2[ %IF3-[N(S)F]W$NO22!:9DS>[B$DF(MT5Q=@"$U$D(2    %
M7F'772A',NWH!3!4YEV]!S+MZ 4P5>9=O0<R[>@%(%3F7;T)YEV] *0*O,NW
MH0D%V] *8*G,NWH.9=O0"F"IS+MZ#F7;T I@JI!=O0CF7;T I@J<R[>@YEV]
M *8*G,NWH.9=O0"F"JD%V]".9=O0"F"IS+MZ$\R[>@%(%3F7;T)YEV] *0*G
M,NWH$@NMK0"F05>9=ITH.9=O0"C=.TGB5>9=O0<R[>@%*_G'$J\R[>@YEV]H
M%*X0J\R[>@YEV] *7$7\Y5YEV]!S+M.E *7$%7F7;T',NWH!2XCB54@NWH$@
MNWH!2'$JI!=O0<RZ^M *(XE;F7;T',NWH!1)XE7F7;VCF7;T I7\XOYRKS+M
MZ#F7;T I7\Y"J5^9=O0CF7;T I(HXE7F7;T',NWH!2NG:.)52"[>@2"[>T"E
MH[1<J\R[>@YEV] *0N5>9=;6@YEV] *5_..)5YEV]!S+MZ 4K^<7\Y5YEV]!
MS+MZ 4KA/25>9=O0<R[>@%&_G)*J07;T',NWH!2N25.9=O0GF7;T I J<R[>
MA/,NWH!2!4YEV] D%UM: 4P5.9===*#F7;T I@J<R[>@YEV] *8*O,NWH.9=
MO0"D"KS+MZ#F';T I J<R[>@YEV] *8*O,NWH.8=O0"D"KS+MZ$<R[>@%,%5
M(+MZ$<R[>@%,%7F7;T(YEV] *8*G,.WH.9=O0"F"IS+MZ#F7;T I@J\R[>A'
M,NWH!3!4YEV]">9=O0"D"KS+MZ!(+MZ 4@5.9=O0<R[>@%,%3F76UH.9=O0"
MF"JD%V]".9=O0"F"IS+MZ#F7;T I@J<R[>@YEV] *8*J07;T(YEV] *8*G,N
MWH3S+MZ 4@5.9=O0GF7;T I J<R[>@2"ZVM *8*G,NNNE!S+MZ 4P5.9=O0<
MR[>@%,%7F7;T',NWH!2!5YEV]!S#MZ 4@5.9=O0<R[>@%,%7F7;T',NWH!2!
M52"[>A',NWH!3!52"[>A',NWH!3!5YEV]".9=O0"F"IS#MZ#F7;T I@J<R[>
M@YEV] *8*O,NWH.9=O0"D"IS+MZ$\R[>@%(%7F7;T(2"[>@%,%3F7;T',NWH
M!3!4YEV]!S+MZ 4P54@NWH1S+MZ 4P5.9=O0<R[>@%,%3F7;T',NWH!3!52"
M[>A',NWH!3!4YEV]">9=O0"D"IS+MZ$\R[>@%(%3F7;T"076UH!3!4YEVG2@
MYEV] *8*G,NWH.9=O0"F"KS+MZ$<R[>@%,%7F7;T',.WH!2!4YEV]!S+MZ 4
MP5>9=O0<P[>@%(%5(+MZ$<R[>@%,%5(+MZ$<R[>@%,%7F7;T(YEV] *8*G,.
MWH.9=O0"F"IS+MZ#F7;T I@J\R[>@YEV] *0*G,NWH3S+MZ 4@5>9=O0A(+M
MZ 4P5.9=O0<R[>@%,%3F76UH.9=O0"F"JD%V]".9=O0"F"IS+MZ#F7;T I@J
M<R[>@YEV] *8*J07;T(YEV] *8*G,NWH3S+MZ 4@5.9=O0GF7;T I J<R[>@
M2"ZVM *8*G,NNNE!S+MZ 4P5.9=O0<R[>@%,%7F7;T',NWH!2!5YEV]!S#MZ
M 4@5.9=O0<R[>@%,%7F7;T',.WH!2!5YEV]".9=O0"F"JD%V]".9=O0"F"KS
M+MZ$<R[>@%,%3F7;T)YEV] *0*G,NWH.9=O0"F"IS+MZ!(#MZ 4P5>9=O0 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Apr. 27, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001829802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Sensei Biotherapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>Apr. 27, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457aFlg', window );">Rule 457(a)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stok, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">24,868,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">31.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 775,385,113.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 107,080.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Consists of an aggregate of up to 24,868,028 shares of the Registrant's common stock, par value $0.0001 per share (the "Common Stock) consisting of (i) 10,425,531 shares of Common Stock, issuable upon the conversion of 10,425.531 shares of the Registrant's Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share ("Series B Preferred Stock"), (ii) 14,440,395 shares of Common Stock issuable upon the conversion of 14,440.395 shares of Series B Preferred Stock and (iii) 2,102 shares of Common Stock issuable upon exercise of a warrant to purchase 2.1020 shares of Series B Preferred Stock, which will be exercisable for shares of Common Stock upon conversion of the Series B Preferred Stock. Pursuant to Rule 416 under the Securities Act of 1933, as amended, the shares of Common Stock being registered hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock being registered hereunder as a result of stock splits, stock dividends or similar transactions. Pursuant to Rule 457(c) under the Securities Act, calculated on the basis of the average of the high and low prices per share of Common Stock reported on The Nasdaq Stock Market on April 21, 2026.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457aFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457aFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Apr. 27, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 775,385,113.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">107,080.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 107,080.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="d133316dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d133316dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d133316dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="d133316dexfilingfees.htm">d133316dexfilingfees.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/ffd/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d133316dexfilingfees.htm": {
   "dts": {
    "inline": {
     "local": [
      "d133316dexfilingfees.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/ffd/2026": 6,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2026": 22,
    "http://xbrl.sec.gov/dei/2026": 3
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d133316dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d133316dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d133316dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d133316dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal8ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2026",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-26-183535-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-183535-xbrl.zip
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J,S$V9&5X9FEL:6YG9F5E<RYH=&U02P4&      $  0!&    ' P

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d133316dexfilingfees_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001829802</identifier>
        </entity>
        <period>
            <startDate>2026-04-27</startDate>
            <endDate>2026-04-27</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001829802</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-27</startDate>
            <endDate>2026-04-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-331">S-3</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-332">S-3</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-333">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-334">0001829802</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-335">Sensei Biotherapeutics, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="rc" id="ixv-363">S-3</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-364">Sensei Biotherapeutics, Inc.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="offrl_1" id="ixv-365">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-366">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-367">Common Stok, par value $0.0001 per share</ffd:OfferingSctyTitl>
    <ffd:Rule457aFlg contextRef="offrl_1" id="ixv-368">true</ffd:Rule457aFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_1"
      decimals="0"
      id="ixv-369"
      unitRef="Shares">24868028</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="offrl_1"
      decimals="2"
      id="ixv-370"
      unitRef="USD">31.18</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="2"
      id="ixv-371"
      unitRef="USD">775385113.04</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="7"
      id="ixv-372"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_1"
      decimals="2"
      id="ixv-373"
      unitRef="USD">107080.68</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="2" id="ixv-374" unitRef="USD">775385113.04</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="2" id="ixv-375" unitRef="USD">107080.68</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="2" id="ixv-376" unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="2" id="ixv-377" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="2" id="ixv-378" unitRef="USD">107080.68</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-379">Consists of an aggregate of up to 24,868,028 shares of the Registrant's common stock, par value $0.0001 per share (the "Common Stock) consisting of (i) 10,425,531 shares of Common Stock, issuable upon the conversion of 10,425.531 shares of the Registrant's Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share ("Series B Preferred Stock"), (ii) 14,440,395 shares of Common Stock issuable upon the conversion of 14,440.395 shares of Series B Preferred Stock and (iii) 2,102 shares of Common Stock issuable upon exercise of a warrant to purchase 2.1020 shares of Series B Preferred Stock, which will be exercisable for shares of Common Stock upon conversion of the Series B Preferred Stock. Pursuant to Rule 416 under the Securities Act of 1933, as amended, the shares of Common Stock being registered hereunder include such indeterminate number of shares of Common Stock as may be issuable with respect to the shares of Common Stock being registered hereunder as a result of stock splits, stock dividends or similar transactions. Pursuant to Rule 457(c) under the Securities Act, calculated on the basis of the average of the high and low prices per share of Common Stock reported on The Nasdaq Stock Market on April 21, 2026.</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
